JP5247667B2 - Medicine - Google Patents

Description

  The present invention relates to a medicine.

  Parkinson's disease is a neurodegenerative disease that usually begins after middle age and progresses chronically. As for the first symptom, resting tremor is seen in one side, and immobility and rigidity are added to this. This tremor, ataxia, and stiffness are called the three major signs of Parkinson's disease, all of which are caused by the selective loss of dopamine-containing neurons that project from the midbrain substantia nigra to the striatum. ing. The etiology of this disease remains unclear, but there is evidence that a disorder in the energy production system associated with mitochondrial dysfunction in the midbrain nigrostriatal dopaminergic neurons is the cause of neurodegenerative injury in this disease. It is accumulating. This mitochondrial dysfunction is thought to degenerate nerve cells by causing subsequent oxidative stress and calcium homeostasis failure (Non-patent Document 1).

  Treatment of Parkinson's disease is broadly divided into medical treatment (pharmacotherapy) and surgical treatment (stereoscopic brain surgery). Of these, pharmacotherapy is an established treatment and is considered the basis of treatment. In the drug therapy here, symptomatic therapeutic drugs are used for the purpose of compensating for the function of the midbrain nigrostriatal dopaminergic nerve that has degenerated and dropped out due to Parkinson's disease. It is said that L-dopa shows the most excellent therapeutic effect, and no drug exceeds this. Currently, when L-dopa is used, a dopa decarboxylase inhibitor that suppresses peripheral metabolism is used in combination, and an expected clinical effect is obtained.

  However, L-DOPA therapy has a difficulty that, within a few years after its start of use, with the recurrence of motor dysfunction such as dyskinesia, the sustainability and stability of the effect are impaired, and circadian variation appears. In addition, side effects of gastrointestinal symptoms such as nausea and vomiting due to excess dopamine, cardiovascular symptoms such as orthostatic hypotension, arrhythmia and arrhythmia, and psychiatric symptoms such as hallucinations, delusions and confusion are problematic.

  Therefore, in order to reduce the dose of L-dopa preparation and reduce side effects, multi-drug combination therapy using a combination of dopamine receptor agonists, dopamine metabolizing enzyme inhibitors, dopamine release promoters, central anticholinergic agents, etc. Has been done. Although the prognosis has been considerably improved by the progress of such treatment, a fundamental treatment for other neurodegenerative diseases including Parkinson's disease has not yet been established. Drug therapy must be carried out for a lifetime, and L-dopa monotherapy has problems such as a decrease in drug efficacy, side effects, and inability to suppress disease progression due to long-term administration as described above. In addition, it is difficult to expect dramatic therapeutic effects even if multidrug combination therapy is performed.

  Alzheimer's disease is a neurodegenerative disease in which various cognitive functions are affected progressively, mainly in memory impairment. Pathologically, it is characterized by the accumulation of two types of abnormal fibers: degeneration and loss of neurons and synapses in the hippocampus and cerebral cortex, and senile plaques and neurofibrillary tangles. The etiology of this disease has not been fully elucidated, but amyloid β protein (Aβ) excised from amyloid precursor protein (APP) by various mechanisms plays an important role. Currently, in the treatment of Alzheimer's disease, the acetylcholinergic nervous system in the brain is deeply involved in cognitive function, and a significant disorder has been observed in this nervous system. , Aricept, Rivastigmine, Galantamine) have been used for the purpose of reducing symptoms. In addition, glutamate N-methyl-D-aspartate receptor antagonist (memantine) has been put to practical use because excessive excitability of glutamate neurotransmission mechanism is related to neuronal degeneration and damage. However, in the drug treatment using these, a sufficient therapeutic effect cannot be obtained even in a single agent or a combination therapy used in combination, and the progression of the disease cannot be stopped. Further, cholinesterase inhibitors have gastrointestinal symptoms such as nausea and diarrhea as side effects.

  In addition, for ischemic neurodegenerative disorders caused by cerebral infarction such as atherothrombotic cerebral infarction, lacunar infarction and cardiogenic cerebral embolism, the hyperacute phase using tissue type plasminogen activator (tPA) Although thrombolytic therapy is rapidly spreading, it has many problems including a narrow time window of 3 hours after onset and bleeding complications.

  On the other hand, free radical scavenger edaravone is used as a brain protection therapy in Japan, and it can be used in combination with tPA. However, sufficient clinical effects have not been obtained.

  For these reasons, there is a strong demand for drugs having new mechanisms of action and neuroprotective agents that prevent neuronal degeneration and damage from mitochondrial dysfunction, which is one of the etiologies.

Ann.N.Y.Acad.Sci.991: 111-119 (2003)

  The present invention inhibits the progressive progression of Parkinson's disease or suppresses the progression of neurological dysfunction by protecting dopamine neurons from its pathogenesis, and has an effect of improving the function while extending the period until L-dopa administration. It is an object to provide a novel compound.

  In addition, the present invention provides a drug useful for the treatment of a disease associated with cell death, more specifically, a drug effective for the treatment of Alzheimer's disease or the improvement of dysfunction or neurological deficits caused by a stroke. The task is to do.

  As a result of intensive studies to solve the above problems, the present inventors have found a compound represented by the following general formula (1) having a mitochondria function protection improving action and / or a nerve cell protection / function repair action. Successfully synthesized. The present invention has been completed based on such findings.

  The present invention provides the medicaments, pharmaceutical compositions, and methods for treating or preventing diseases shown in the following items 1 to 9.

  Item 1. General formula (1)

[Where:
R ₁ represents hydrogen, a lower alkyl group, a cycloC3-C8 alkyl lower alkyl group or a lower alkoxy lower alkyl group.
R ₂ represents hydrogen, a lower alkyl group or a halogen-substituted lower alkyl group.
R ₃ represents a phenyl group, a furyl group, a thienyl group or a pyridyl group.
Here, one or more groups selected from the group consisting of the following (1) to (16) may be substituted on the aromatic ring and heterocyclic ring represented by R ₃ :
(1) a lower alkyl group,
(2) a lower alkoxy group,
(3) a halogen-substituted lower alkoxy group,
(4) phenoxy group,
(5) a lower alkylthio group,
(6) a hydroxy group,
(7) hydroxy lower alkyl group,
(8) halogen,
(9) a lower alkanoyl group,
(10) a lower alkoxycarbonyl group,
(11) an amino group optionally substituted by one or more lower alkyl groups,
(12) a carbamoyl group optionally substituted by one or more lower alkyl groups,
(13) a cyclo C3-C8 alkyl lower alkoxy group,
(14) pyrrolidinylcarbonyl group,
(15) A morpholinylcarbonyl group and (16) a carboxyl group R ₄ represent halogen.
R ₅ represents hydrogen or halogen.
R ₆ represents hydrogen.
R ₇ represents any one of the following groups (1) to (15).
(1) a hydroxy group,
(2) halogen,
(3) a lower alkoxy group,
(4) a halogen-substituted lower alkoxy group,
(5) hydroxy lower alkoxy group,
(6) Lower alkoxy lower alkoxy group,
(7) an amino group which may be substituted with one or more groups selected from the group consisting of a lower alkyl group, a lower alkoxy lower alkyl group and a cyclo C3-C8 alkyl group;
(8) Amino lower alkoxy group (here, selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkylsulfonyl group, and a carbamoyl group optionally having one or more lower alkyl groups on the amino group) One or more groups may be present),
(9) a cyclo C3-C8 alkyloxy group,
(10) a cyclo C3-C8 alkyl lower alkoxy group,
(11) Tetrahydrofuryl lower alkoxy group,
(12) a lower alkylthio group,
(13) A heterocyclic group selected from the group consisting of a morpholinyl group, a pyrrolidinyl group, a furyl group, a thienyl group, and a benzothienyl group,
(14) phenyl lower alkoxy lower alkoxy group, and (15) pyrrolidinylcarbonyl group]
The pharmaceutical which consists of quinolone compound represented by these, or its salt.

Item 2. R ₁ represents hydrogen or a lower alkyl group, R ₂ represents hydrogen or a lower alkyl group, on the aromatic ring and heterocyclic ring represented by R ₃ is a phenyl group or a pyridyl group (said R _3, below (1) , (2), (6) and (8) may be substituted by one or two groups selected from the group consisting of:
(1) a lower alkyl group,
(2) a lower alkoxy group,
(6) a hydroxy group,
(8) halogen), R ₄ represents halogen, R ₅ represents hydrogen, R ₆ represents hydrogen, and R ₇ represents the following (3), (4) and (7):
(3) a lower alkoxy group,
(4) a halogen-substituted lower alkoxy group,
(7) The quinolone compound represented by the general formula (1) according to Item 1 or a salt thereof, which represents any one of amino groups optionally substituted by one or two lower alkyl groups. Medicine.

Item 3. A pharmaceutical comprising the quinolone compound represented by the general formula (1) according to item 2 or a salt thereof selected from the group shown below:
5-fluoro-3- (4-methoxyphenyl) -2-methyl-8-propoxy-1H-quinolin-4-one,
5-fluoro-3- (4-methoxyphenyl) -1-methyl-8-propoxy-1H-quinolin-4-one,
3- (2,4-dimethoxyphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one,
5-fluoro-8-isopropoxy-3- (4-methoxyphenyl) -1H-quinolin-4-one,
3- (2,4-dichlorophenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one,
8-ethoxy-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one,
5-fluoro-3- (4-methoxy-2-methylphenyl) -8-propoxy-1H-quinolin-4-one,
5-fluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one,
5-fluoro-3- (2-fluoro-4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one,
5-fluoro-3- (4-hydroxyphenyl) -8-propoxy-1H-quinolin-4-one,
8-cyclopropylmethoxy-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one,
5-fluoro-8-propoxy-3-pyridin-4-yl-1H-quinolin-4-one,
5-fluoro-3- (4-methoxyphenyl) -8- (N-methyl-N-propylamino) -1H-quinolin-4-one, and 5-fluoro-3- (4-methoxyphenyl) -8- (4,4,4-trifluorobutoxy) -1H-quinolin-4-one.

Item 4. Item 4. A pharmaceutical composition comprising the pharmaceutical according to any one of Items 1 to 3 and a pharmacologically acceptable carrier.

Item 5. A therapeutic and prophylactic agent for a neurodegenerative disease, a disease associated with a disorder of neurological function, or a disease associated with a decrease in mitochondrial function, comprising the medicine according to any one of Items 1 to 3 as an active ingredient.

Item 6. Neurodegenerative diseases are Parkinson's disease, Parkinson's syndrome, juvenile Parkinsonism, striatal nigra degeneration, progressive supranuclear palsy, pure ataxia, Alzheimer's disease, Pick's disease, prion disease, basal ganglia degeneration Disease, diffuse Lewy body disease, Huntington's disease, spiny erythrocytic chorea, benign hereditary chorea, paroxysmal choreoathetosis, essential tremor, essential myoclonus, Gilles de la Tourette syndrome, Rett syndrome, Degenerative balism, Degenerative muscular dystonia, Athetosis, Spastic torticollis, Mage syndrome, Cerebral palsy, Wilson disease, Segawa disease, Hallelfolden-Spatz syndrome, Axonal dystrophy, Pallus atrophy, Spinocerebellar degeneration, Cortical cerebellar atrophy, Holmes cerebellar atrophy, olive bridge cerebellar atrophy, hereditary olive bridge cerebellar atrophy, Joseph's disease, dentate nucleus red Ryukyu Ryu atrophy, Gerstmann-Stroisler-Scheinka syndrome, Friedreich ataxia, Lucy Levy syndrome, May-White syndrome, congenital cerebellar ataxia, periodic hereditary ataxia, telangiectasia , Amyotrophic lateral sclerosis, progressive bulbar paralysis, spinal progressive amyotrophy, bulbospinal muscular atrophy, Weldnig-Hoffmann disease, Kugelberg-Wehlander disease, hereditary spastic paraplegia, syringomyelia , Syringomyelia, Arnold Kiary malformation, stiff man syndrome, Klippel file syndrome, phathiorond disease, hypomyelopathy, dandy walker syndrome, spina bifida, Sjogren Larson syndrome, radiation myelopathy, age-related macular degeneration, And a stroke selected from cerebral infarction and cerebral hemorrhage and / or associated dysfunction or Is a disease selected from the group consisting of through deficit, therapeutic and prophylactic agent according to claim 5.

Item 7. Diseases associated with impaired neurological function include spinal cord injury, chemotherapy-induced neuropathy, diabetic neuropathy, radioactivity disorder, and multiple sclerosis, acute disseminated encephalomyelitis, transverse myelitis, progressive multiple Item 6. The therapeutic and prophylactic agent according to Item 5, which is a demyelinating disease selected from focal leukoencephalopathy, subacute sclerosis panencephalitis, chronic inflammatory demyelinating polyradiculoneuritis and Guillain-Barre syndrome.

Item 8. Diseases associated with decreased mitochondrial function include Pearson's syndrome, diabetes, hearing loss, malignant migraine, Leber's disease, MELAS, MERRF, MERRF / MERAS duplication syndrome, NARP, pure myopathy, mitochondrial cardiomyopathy, myopathy , Dementia, gastrointestinal ataxia, acquired ironblastic anemia, aminoglycoside-induced hearing loss, complex III deficiency due to cytochrome b gene mutation, symmetric polylipomatosis, ataxia, myoclonus, retinopathy, MNGIE, ANT1 Abnormalities, twinkle abnormalities, POLG abnormalities, repetitive myoglobinuria, SANDO, ARCO, complex I deficiency, complex II deficiency, optic atrophy, complex IV deficient severe infant type, mitochondrial DNA deficiency syndrome, Lee Encephalopathy, Chronic Progressive Extraocular Muscle Paralysis Syndrome (CPEO), Keynes-Sayer Syndrome, Encephalopathy, Lacticemia, Myoglobinuria, Drug-induced Mitoko Doria disease, schizophrenia, major depressive disorder, bipolar type I disorder, bipolar type II disorder, mixed state, dysthymic disorder, atypical depression, seasonal emotional disorder, postpartum depression, mild depression, repetitive Item 6. The therapeutic and prophylactic agent according to Item 5, which is sexual short-term depression disorder, refractory depression, chronic depression, double depression and acute renal failure.

Item 9. An ischemic heart disease and / or dysfunction associated therewith, heart failure, cardiomyopathy, aortic divergence, immunodeficiency, containing the quinolone compound represented by the general formula (1) or a salt thereof according to item 1 as an active ingredient, Autoimmune disease, pancreatic insufficiency, diabetes, atheroembolic kidney disease, polycystic kidney disease, medullary cystic disease, renal cortical necrosis, malignant nephrosclerosis, renal failure, hepatic encephalopathy, liver failure, chronic obstructive pulmonary disease, Treatment of diseases of pulmonary embolism, bronchiectasis, silicosis, black lung, idiopathic pulmonary fibrosis, Stevens-Johnson syndrome, toxic epidermal necrosis, muscular dystrophy, clostridial muscle necrosis and femoral condylar osteonecrosis And / or preventive agent.

  Specifically, each group shown in the general formula (1) is as follows.

  Examples of the lower alkyl group include linear or branched alkyl groups having 1 to 6 carbon atoms (preferably 1 to 4 carbon atoms). More specifically, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-ethylpropyl, isopentyl, neopentyl, n-hexyl, 1,2 , 2-trimethylpropyl, 3,3-dimethylbutyl, 2-ethylbutyl, isohexyl, 3-methylpentyl group and the like.

  Examples of the cyclo C3-C8 alkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.

  Examples of the cyclo-C3-C8 alkyl lower alkyl group include the above-described lower alkyl groups having 1 to 3 (preferably 1) of the above-mentioned cyclo C3-C8 alkyl groups.

  Examples of the lower alkoxy group include linear or branched alkoxy groups having 1 to 6 carbon atoms (preferably 1 to 4 carbon atoms). More specifically, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, sec-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, iso Hexyloxy, 3-methylpentyloxy groups and the like are included.

  Examples of the lower alkoxy lower alkyl group include the lower alkyl groups exemplified above having 1 to 3 (preferably 1) lower alkoxy groups exemplified above.

  Examples of the halogen atom include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.

  Examples of the halogen-substituted lower alkyl group include the above-described lower alkyl groups substituted with 1 to 7, more preferably 1 to 3, halogen atoms. More specifically, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, dichlorofluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl , Pentafluoroethyl, 2-fluoroethyl, 2-chloroethyl, 3,3,3-trifluoropropyl, heptafluoropropyl, 2,2,3,3,3-pentafluoropropyl, heptafluoroisopropyl, 3-chloropropyl 2-chloropropyl, 3-bromopropyl, 4,4,4-trifluorobutyl, 4,4,4,3,3-pentafluorobutyl, 4-chlorobutyl, 4-bromobutyl, 2-chlorobutyl, 5,5 , 5-trifluoropentyl, 5-chloropentyl, 6, , Hexyl 6-trifluoromethyl, 6-chloro hexyl, perfluorohexyl group or the like.

  Examples of the halogen-substituted lower alkoxy group include the exemplified lower alkoxy groups substituted with 1 to 7, preferably 1 to 3, halogen atoms. More specifically, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, bromomethoxy, dibromomethoxy, dichlorofluoromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy, 2 -Chloroethoxy, 3,3,3-trifluoropropoxy, heptafluoropropoxy, heptafluoroisopropoxy, 3-chloropropoxy, 2-chloropropoxy, 3-bromopropoxy, 4,4,4-trifluorobutoxy, 4, 4,4,3,3-pentafluorobutoxy, 4-chlorobutoxy, 4-bromobutoxy, 2-chlorobutoxy, 5,5,5-trifluoropentoxy, 5-chloropentoxy, 6,6,6- Trifluorohexyloxy, 6- Rollo hexyloxy group and the like.

  Examples of the lower alkylthio group include an alkylthio group in which the alkyl moiety is the lower alkyl group exemplified above.

  Examples of the hydroxy lower alkyl group include the above-described lower alkyl groups having 1 to 3 (preferably 1) hydroxy groups.

  Examples of the lower alkanoyl group include linear or branched alkanoyl groups having 1 to 6 carbon atoms (preferably 1 to 4 carbon atoms). More specifically, formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, tert-butylcarbonyl, hexanoyl group and the like are included.

  Examples of the lower alkoxycarbonyl group include an alkoxycarbonyl group in which the alkoxy moiety is the lower alkoxy group exemplified above.

  Examples of the amino group which may be substituted by one or more lower alkyl groups include an amino group optionally having 1 to 2 lower alkyl groups as exemplified above.

  Examples of the carbamoyl group optionally substituted by one or more lower alkyl groups include carbamoyl groups optionally having 1 to 2 lower alkyl groups as exemplified above.

  Examples of the cyclo C3-C8 alkyl lower alkyl group include the above-described lower alkyl groups having 1 to 3 (preferably 1) of the above-mentioned cyclo C3-C8 alkyl groups.

  Examples of the hydroxy lower alkoxy group include the above-described lower alkoxy groups having 1 to 3 (preferably 1) hydroxy groups.

  Examples of the lower alkoxy-lower alkoxy group include the above-exemplified lower alkoxy groups having 1 to 3 (preferably 1) the above-mentioned lower alkoxy groups.

  Examples of the amino group which may be substituted with one or more groups selected from the group consisting of a lower alkyl group, a lower alkoxy lower alkyl group and a cyclo C3-C8 alkyl group include, for example, the lower alkyl groups exemplified above and the above examples. And an amino group optionally having 1 to 2 groups selected from the group consisting of the above-described lower C3-C8 alkyl.

  Examples of the lower alkylsulfonyl group include an alkylsulfonyl group in which the alkyl moiety is the lower alkyl group exemplified above.

  An amino lower alkoxy group (here, a group selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkylsulfonyl group, and a carbamoyl group optionally having one or more lower alkyl groups on the amino group) May be one or more of the above-mentioned lower alkoxy groups having 1 to 3 (preferably 1) amino groups. Here, the amino lower alkoxy group may have the above-illustrated lower alkyl group, the exemplified lower alkanoyl group, the exemplified lower alkylsulfonyl group, and the exemplified lower alkyl group on the amino group. It may have 1 to 2 groups selected from the group consisting of good carbamoyl groups.

  Examples of the cyclo C3-C8 alkyloxy group include a group in which the above-exemplified cyclo C3-C8 alkyl group and an oxygen atom are bonded.

  Examples of the tetrahydrofuryl lower alkoxy group include the lower alkoxy groups exemplified above having 1 to 3 (preferably 1) tetrahydrofuryl groups.

  Examples of the lower alkylthio group include an alkylthio group in which the alkyl moiety is the lower alkyl group exemplified above.

  Examples of the phenyl lower alkoxy group include the lower alkoxy groups exemplified above having 1 to 3 (preferably 1) phenyl groups.

  Examples of the phenyl lower alkoxy lower alkoxy group include the lower alkoxy groups exemplified above having 1 to 3 (preferably 1) phenyl lower alkoxy groups exemplified above.

  The production method of the compound of the present invention will be described below.

The quinolone compound represented by the general formula (1) (hereinafter sometimes referred to as the compound (1)) can be produced by various methods. For example, the following reaction formula-1 or reaction can be given. It is manufactured by the method shown by Formula-2.
[Reaction Formula-1]

[Wherein, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , R ₆ and R ₇ are the same as defined above, and X ₁ represents a halogen atom. ]
Examples of the halogen atom represented by X ₁ include fluorine, chlorine, bromine and iodine.

  In this reaction, a preferable leaving group includes halogen, and iodine is particularly preferable.

  The compound represented by the general formula (2) and the compound represented by the general formula (3) are reacted in a solvent-free or inert solvent in the presence or absence of a basic compound and in the presence of a palladium catalyst. Compound (1) can be produced.

  Examples of the inert solvent include water; ether solvents such as dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; Lower alcohol solvents such as methanol, ethanol, isopropanol; ketone solvents such as acetone and methyl ethyl ketone; polar solvents such as N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile be able to. These inert solvents are used individually by 1 type or in mixture of 2 or more types.

  Although it does not specifically limit as a palladium compound used in this reaction, For example, tetravalent palladium catalysts, such as sodium hexachloro palladium (IV) acid tetrahydrate and potassium hexachloro palladium (IV); II), palladium (II) bromide, palladium (II) acetate, palladium acetylacetonate (II), dichlorobis (benzonitrile) palladium (II), dichlorobis (acetonitrile) palladium (II), dichlorobis (triphenylphosphine) palladium (II), dichlorotetraamminepalladium (II), dichloro (cycloocta-1,5-diene) palladium (II), palladium trifluoroacetate (II), 1,1′-bis (diphenylphosphino) ferrocene Divalent palladium catalysts such as ropalladium (II) -dichloromethane complex; tris (dibenzylideneacetone) dipalladium (0), tris (dibenzylideneacetone) dipalladium chloroform complex (0), tetrakis (triphenylphosphine) palladium ( And 0) palladium catalysts such as 0). These palladium compounds are used individually by 1 type or in mixture of 2 or more types.

  In this reaction, the amount of the palladium catalyst used is not particularly limited, but is usually in the range of 0.000001 to 20 mol in terms of palladium with respect to 1 mol of the compound of the general formula (2). The more preferable usage-amount of a palladium compound is the range of 0.0001-5 mol in conversion of palladium with respect to 1 mol of compounds of General formula (2).

  This reaction proceeds advantageously in the presence of an appropriate ligand. Examples of the ligand for the palladium catalyst include 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl (BINAP), tri-o-tolylphosphine, bis (diphenylphosphino) ferrocene, triphenylphosphine, Tri-t-butylphosphine, 9,9-dimethyl-4,5-bis (diphenylphosphino) xanthene (XANTPHOS), or the like can be used. These ligands are used alone or in combination of two or more.

  The usage ratio of the palladium catalyst and the ligand is not particularly limited. The amount of the ligand used is about 0.1 to 100 mol, preferably about 0.5 to 15 mol, per 1 mol of the palladium catalyst.

  As the basic compound, known inorganic bases and organic bases can be widely used.

  Examples of the inorganic base include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, and lithium hydroxide; alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, and lithium carbonate; hydrogen carbonate Alkali metal hydrogen carbonates such as lithium, sodium hydrogen carbonate and potassium hydrogen carbonate; Alkali metals such as sodium and potassium; Phosphate salts such as sodium phosphate and potassium phosphate; Amides such as sodium amide; Sodium hydride and hydrogenated Examples thereof include alkali metal hydrides such as potassium.

  Examples of organic bases include alkali metal lower alkoxides such as sodium methoxide, sodium ethoxide, sodium t-butoxide, potassium methoxide, potassium ethoxide, potassium t-butoxide; triethylamine, tripropylamine, pyridine, quinoline, piperidine , Imidazole, N-ethyldiisopropylamine, dimethylaminopyridine, trimethylamine, dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo [4.3.0] nonene-5 (DBN), 1,8-diazabicyclo [5. And amines such as 4.0] undecene-7 (DBU) and 1,4-diazabicyclo [2.2.2] octane (DABCO).

  These basic compounds are used individually by 1 type or in mixture of 2 or more types. More preferably, the basic compound used in this reaction includes alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, and lithium carbonate.

  The usage-amount of a basic compound is 0.5-10 times mole normally with respect to the compound of General formula (2), Preferably it is 0.5-6 times mole.

  The usage ratio of the compound of the general formula (2) and the compound of the general formula (3) in the above reaction formula-1 is usually set to at least equimolar, preferably equimolar to 5-fold molar, with respect to the former. .

  This reaction can be performed under normal pressure, under an inert gas atmosphere such as nitrogen or argon, or under pressure.

  The above reaction is usually performed at room temperature to 200 ° C, preferably room temperature to 150 ° C, and is generally completed in about 1 to 30 hours. It can also be achieved by heating at 100 to 200 ° C. for 5 minutes to 1 hour using a microwave reactor.

The compound represented by the general formula (3) used as a starting material in the above reaction formula-1 is a known compound that is easily available. The compound represented by the general formula (2) includes a novel compound, and the compound is produced, for example, according to the method shown in the following reaction formula-6.
[Reaction Formula-2]

[Wherein, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , R ₆ and R ₇ are the same as described above, and R ₈ represents a lower alkoxy group. ]
In the general formula (5), the lower alkoxy group represented by R ₈ has the same definition as described above.

  By reacting the compound represented by the general formula (4) with the compound represented by the general formula (5) in a solvent-free or inert solvent in the presence or absence of an acid catalyst, the general formula (6) The compound of the general formula (1) can be produced by obtaining an intermediate compound represented by

  Examples of the inert solvent include water; ether solvents such as dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; Examples include lower alcohol solvents such as methanol, ethanol and isopropanol; polar solvents such as N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide and acetonitrile. These inert solvents are used individually by 1 type or in mixture of 2 or more types.

  As the acid catalyst, known ones can be widely used, and examples thereof include acids such as toluenesulfonic acid, methanesulfonic acid, xylenesulfonic acid, sulfuric acid, glacial acetic acid, boron trifluoride and acidic ion exchangers. These acid catalysts are used singly or in combination of two or more.

  Among these acids, it is preferable to use an acidic ion exchanger, and examples of the acidic ion exchanger include commercially available polymer cation exchangers such as Lewatit S100 and Zeo-carb 225. Styrene sulfonic acid polymers such as Dowex 50, Amberlite IR120 or Amberlyst 15; polysulfonic acid condensates such as Rewacit PN or Zeocarb 215 or 315; Rewacit CNO or Duolite ( Duolite) m-phenol carboxylic acid resin such as CS100; or polyacrylic acid esters such as Permutit C, Zeo-carb 226 or Amberlite IRC50. Among them, in particular to use Amberlyst 15 preferred.

  The usage-amount of an acid catalyst is the range of 0.0001 times mole-100 times mole normally with respect to the compound of General formula (4), Preferably it is 0.5-6 times mole.

  The use ratio of the compound of the general formula (4) and the compound of the general formula (5) in the above reaction formula-2 is usually such that the latter is at least equimolar to the former, preferably about equimolar to 5 times molar. .

  This reaction can be performed under normal pressure, under an inert gas atmosphere such as nitrogen or argon, or under pressure.

  The above reaction is usually performed at room temperature to 200 ° C., preferably at room temperature to 150 ° C., during which time water is removed azeotropically until the generation of reaction water is completed, and is generally completed in about 1 to 30 hours. To do.

  The step of producing the compound represented by the general formula (1) from the intermediate compound represented by the general formula (6) by a cyclization reaction can be carried out by heating in a solvent such as diphenyl ether, It can also be carried out by heating the compound even in the absence of a solvent. The reaction is carried out at 150 to 300 ° C. for 5 minutes to 2 hours.

The compound represented by the general formula (4) used as a starting material in the above reaction formula-2 is a known compound or can be easily produced from a known compound. The compound represented by the general formula (5) includes a novel compound, and the compound is produced, for example, according to the methods shown in the following reaction formula-4 and the following reaction formula-5.
[Reaction Formula-3]

[Wherein R ₂ , R ₃ , R ₄ , R ₅ , R ₆ and R ₇ are the same as above, R ₁ ′ is a group represented by R ₁ other than hydrogen, and X ₂ is a halogen Or the group which causes the substitution reaction similar to a halogen atom is shown. ]
In the general formula (7), examples of the halogen represented by X ₂ include the halogen atoms exemplified above. Examples of the group that causes the same substitution reaction as the halogen atom represented by X ₂ include a lower alkanesulfonyloxy group, an arylsulfonyloxy group, an aralkylsulfonyloxy group, and the like.

  Specific examples of the lower alkanesulfonyloxy group include methanesulfonyloxy, ethanesulfonyloxy, n-propanesulfonyloxy, isopropanesulfonyloxy, n-butanesulfonyloxy, tert-butanesulfonyloxy, n-pentanesulfonyloxy, n Examples thereof include straight-chain or branched alkanesulfonyloxy groups having 1 to 6 carbon atoms in the hexanesulfonyloxy group.

  Examples of the arylsulfonyloxy group include, for example, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkoxy group having 1 to 6 carbon atoms, and a nitro group as a substituent on the phenyl ring. And phenylsulfonyloxy and naphthylsulfonyloxy groups which may have 1 to 3 groups selected from the group consisting of halogen atoms. Specific examples of the phenylsulfonyloxy group which may have a substituent include phenylsulfonyloxy, 4-methylphenylsulfonyloxy, 2-methylphenylsulfonyloxy, 4-nitrophenylsulfonyloxy, 4-methoxyphenylsulfonyloxy, Examples include 2-nitrophenylsulfonyloxy and 3-chlorophenylsulfonyloxy groups. Specific examples of the naphthylsulfonyloxy group include an α-naphthylsulfonyloxy group and a β-naphthylsulfonyloxy group.

  Examples of the aralkylsulfonyloxy group include, for example, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkoxy group having 1 to 6 carbon atoms, and a nitro group as a substituent on the phenyl ring. And a straight chain or branched alkanesulfonyloxy group having 1 to 3 carbon atoms substituted by a phenyl group which may have 1 to 3 groups selected from the group consisting of halogen atoms, and a carbon number substituted by a naphthyl group Examples thereof include 1 to 6 linear or branched alkanesulfonyloxy groups. Specific examples of the alkanesulfonyloxy group substituted with the phenyl group include benzylsulfonyloxy, 2-phenylethylsulfonyloxy, 4-phenylbutylsulfonyloxy, 4-methylbenzylsulfonyloxy, 2-methylbenzylsulfonyloxy, 4- Examples thereof include nitrobenzylsulfonyloxy, 4-methoxybenzylsulfonyloxy, 3-chlorobenzylsulfonyloxy group and the like. Specific examples of the alkanesulfonyloxy group substituted with the naphthyl group include α-naphthylmethylsulfonyloxy and β-naphthylmethylsulfonyloxy groups.

  By reacting the compound represented by the general formula (1a) with the compound represented by the general formula (7) in a solvent-free or inert solvent in the presence or absence of a basic compound, the general formula (1b) ) Can be produced.

  Examples of the inert solvent include water; ether solvents such as dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; Lower alcohol solvents such as methanol, ethanol, isopropanol; ketone solvents such as acetone and methyl ethyl ketone; polar solvents such as N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile be able to. These inert solvents are used individually by 1 type or in mixture of 2 or more types.

  As the basic compound, known inorganic bases and organic bases can be widely used.

  Examples of the inorganic base include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, and lithium hydroxide; alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, and lithium carbonate; hydrogen carbonate Examples thereof include alkali metal hydrogen carbonates such as lithium, sodium hydrogen carbonate and potassium hydrogen carbonate; alkali metals such as sodium and potassium; amides such as sodium amide; alkali metal hydrides such as sodium hydride and potassium hydride. .

  Examples of organic bases include alkali metal lower alkoxides such as sodium methoxide, sodium ethoxide, sodium t-butoxide, potassium methoxide, potassium ethoxide, potassium t-butoxide; triethylamine, tripropylamine, pyridine, quinoline, piperidine , Imidazole, N-ethyldiisopropylamine, dimethylaminopyridine, trimethylamine, dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo [4.3.0] nonene-5 (DBN), 1,8-diazabicyclo [5. And amines such as 4.0] undecene-7 (DBU) and 1,4-diazabicyclo [2.2.2] octane (DABCO).

  These basic compounds are used individually by 1 type or in mixture of 2 or more types. More preferable examples of the basic compound used in this reaction include inorganic bases such as sodium hydride and potassium hydride.

  The usage-amount of a basic compound is 0.5-10 mol normally with respect to 1 mol of compounds of General formula (1a), Preferably it is 0.5-6 mol.

  In the reaction formula-1, the compound of the general formula (7) is usually used in an amount of at least about 1 mol, preferably about 1 mol to 5 mol, per 1 mol of the compound of the general formula (1a).

  This reaction can be performed under normal pressure, under an inert gas atmosphere such as nitrogen or argon, or under pressure.

  The above reaction is usually performed under a temperature condition of 0 to 200 ° C, preferably room temperature to 150 ° C, and is generally completed in about 1 to 30 hours.

  The compound represented by the general formula (7) used as a starting material in the reaction formula-3 is a known compound that is easily available.

In addition, the compound (5) and the compound (2) which are raw material compounds of the compound of the present invention include a novel compound and can be produced by various methods. For example, the following reaction formulas -4 to 6 can be given. It is manufactured by the method shown by.
[Scheme-4]

[Wherein R ₂ , R ₃ and R ₈ are the same as defined above, and R ₉ represents a lower alkoxy group. ]
In the general formula (9), the lower alkoxy group represented by R ₉ has the same definition as described above.

  By reacting the compound represented by the general formula (8) and the compound represented by the general formula (9) in a solvent-free or inert solvent in the presence or absence of a basic compound, the general formula (5 ) Can be produced.

  Examples of the inert solvent include water; ether solvents such as dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; Lower alcohol solvents such as methanol, ethanol, isopropanol; ketone solvents such as acetone and methyl ethyl ketone; polar solvents such as N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile be able to. These inert solvents are used individually by 1 type or in mixture of 2 or more types.

  As the basic compound, known inorganic bases and organic bases can be widely used.

  Examples of the inorganic base include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, and lithium hydroxide; alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, and lithium carbonate; hydrogen carbonate Alkali metal hydrogen carbonates such as lithium, sodium hydrogen carbonate and potassium hydrogen carbonate; Alkali metals such as sodium and potassium; Amides such as sodium amide; Alkali metal hydrides such as inorganic bases such as sodium hydride and potassium hydride Can be mentioned.

  Examples of organic bases include alkali metal lower alkoxides such as sodium methoxide, sodium ethoxide, sodium t-butoxide, potassium methoxide, potassium ethoxide, potassium t-butoxide; triethylamine, tripropylamine, pyridine, quinoline, piperidine , Imidazole, N-ethyldiisopropylamine, dimethylaminopyridine, trimethylamine, dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo [4.3.0] nonene-5 (DBN), 1,8-diazabicyclo [5. And amines such as 4.0] undecene-7 (DBU) and 1,4-diazabicyclo [2.2.2] octane (DABCO).

  These basic compounds are used individually by 1 type or in mixture of 2 or more types. More preferable examples of the basic compound used in this reaction include inorganic bases such as sodium hydride and potassium hydride.

  The usage-amount of a basic compound is about 1 mol-about 10 mol normally with respect to 1 mol of compounds of General formula (8), Preferably it is about 1 mol-6 mol.

  In the above reaction formula-4, the compound of the general formula (9) is usually used in an amount of at least about 1 mol, preferably about 1 mol to 5 mol, per 1 mol of the compound of the general formula (8).

  This reaction can be performed under normal pressure, under an inert gas atmosphere such as nitrogen or argon, or under pressure.

  The above reaction is usually performed at room temperature to 200 ° C, preferably room temperature to 150 ° C, and is generally completed in about 1 to 30 hours.

The compounds represented by the general formulas (8) and (9) used as starting materials in the above reaction formula-4 are known compounds that are readily available.
[Reaction Formula-5]

[Wherein, R ₂ , R ₃ and R ₈ are the same as defined above, and X ₃ represents a halogen atom. ]
In the general formula (9 ′), the halogen atom represented by X ₃ has the same definition as described above.

  A compound represented by the general formula (8 ′) and a compound represented by the general formula (9 ′) are mixed with a basic compound such as cesium carbonate and copper such as copper iodide in a solvent-free or inert solvent. A compound represented by the general formula (5) can be produced by reacting in the presence of a catalyst.

  As the inert solvent, for example, polar solvents such as N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, and acetonitrile are preferable. These inert solvents are used individually by 1 type or in mixture of 2 or more types.

  This reaction may be performed in the presence of an amino acid such as L-proline.

  This reaction can be performed under normal pressure, under an inert gas atmosphere such as nitrogen or argon, or under pressure.

  The above reaction is usually performed at room temperature to 200 ° C, preferably room temperature to 150 ° C, and is generally completed in about 1 to 30 hours.

  Details of the above reaction are shown in Reference Example 58 described later.

  The compounds represented by the general formulas (8 ′) and (9 ′) used as starting materials in the above Reaction Scheme-5 are known compounds, or can be easily produced from known compounds.

  [Reaction Formula-6]

[Wherein, R ₄ , R ₅ , R ₆ and R ₇ are the same as defined above, and X _1a represents a halogen. R ₁₀ represents a lower alkyl group. ]
The lower alkyl group represented by R ₁₀ and the halogen represented by X _1a have the same definition as described above.
The compound represented by the general formula (4), the compound represented by the general formula (10), and the compound represented by the general formula (11) are subjected to a condensation reaction in a solvent-free or inert solvent. The compound represented by 12) can be produced.

  Examples of the inert solvent include water; ether solvents such as dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether; methylene chloride, chloroform, 1,2-dichloroethane, carbon tetrachloride. Halogenated hydrocarbon solvents such as benzene, toluene, xylene, etc .; lower alcohol solvents such as methanol, ethanol, isopropanol; N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO) And polar solvents such as hexamethylphosphoric triamide and acetonitrile. Moreover, the compound represented by General formula (11) can be used as a solvent instead of the said solvent. These inert solvents are used individually by 1 type or in mixture of 2 or more types.

  The use ratio of the compound of the general formula (4) and the compound of the general formula (10) in the above reaction formula-6 is usually such that the latter is at least equimolar to the former, preferably about equimolar to 5 times molar. .

  The compound represented by the general formula (11) is used in excess with respect to the compound of the general formula (10).

  This reaction can be performed under normal pressure, under an inert gas atmosphere such as nitrogen or argon, or under pressure.

  The above reaction is usually performed at room temperature to 200 ° C, preferably room temperature to 150 ° C, and is generally completed in about 1 to 30 hours.

  The compound represented by the general formula (13) can be produced by cyclizing the compound represented by the general formula (12) in a solvent-free or inert solvent.

  Examples of the inert solvent include ether solvents such as diphenyl ether.

  This reaction can be performed under normal pressure, under an inert gas atmosphere such as nitrogen or argon, or under pressure.

  The above reaction is usually performed at room temperature to 300 ° C, preferably 150 to 300 ° C, and is generally completed in about 1 to 30 hours.

  By reacting the compound represented by the general formula (13) and the compound represented by the general formula (14) in a solvent-free or inert solvent in the presence or absence of a basic compound, the general formula (2a ) Can be produced.

  Examples of the inert solvent include water; ether solvents such as dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; Lower alcohol solvents such as methanol, ethanol, isopropanol; ketone solvents such as acetone and methyl ethyl ketone; polar solvents such as N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile be able to. These inert solvents are used individually by 1 type or in mixture of 2 or more types.

  As the basic compound, known inorganic bases and organic bases can be widely used.

  Examples of the inorganic base include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, and lithium hydroxide; alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, and lithium carbonate; hydrogen carbonate Examples thereof include alkali metal hydrogen carbonates such as lithium, sodium hydrogen carbonate and potassium hydrogen carbonate; alkali metals such as sodium and potassium; amides such as sodium amide; alkali metal hydrides such as sodium hydride and potassium hydride. .

  Examples of organic bases include alkali metal alcoholate solvents such as sodium methoxide, sodium ethoxide, sodium t-butoxide, potassium methoxide, potassium ethoxide, potassium t-butoxide; triethylamine, tripropylamine, pyridine, quinoline, Piperidine, imidazole, N-ethyldiisopropylamine, dimethylaminopyridine, trimethylamine, dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo [4.3.0] nonene-5 (DBN), 1,8-diazabicyclo [5 4.0] undecene-7 (DBU), 1,4-diazabicyclo [2.2.2] octane (DABCO), and other amines.

  These basic compounds are used individually by 1 type or in mixture of 2 or more types. More preferably, the basic compound used in this reaction includes alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate and lithium carbonate.

  The usage-amount of a basic compound is 0.5-10 times mole normally with respect to the compound of General formula (13), Preferably it is 0.5-6 times mole.

  The proportion of the compound of general formula (13) and the compound of general formula (14) used in the above reaction formula-6 is usually at least 0.5 times mol, preferably about 0.5 to 5 times mol of the latter with respect to the former. And it is sufficient.

  This reaction can be performed under normal pressure, under an inert gas atmosphere such as nitrogen or argon, or under pressure.

The above reaction is usually performed at room temperature to 200 ° C, preferably room temperature to 150 ° C, and is generally completed in about 1 to 30 hours.
The compounds represented by the general formulas (10), (11) and (14) used as starting materials in the above reaction formula-6 are known compounds that are readily available.

  The starting compound used in each of the above reaction formulas may be a suitable salt, and the target compound obtained in each reaction may form a suitable salt. Suitable salts thereof include suitable salts of the compound (1) exemplified below.

  Suitable salts of the compound (1) are pharmacologically acceptable salts such as alkali metal salts (for example, sodium salts and potassium salts), alkaline earth metal salts (for example, calcium salts and magnesium salts). Metal salts such as ammonium salts, alkali metal carbonates (for example, lithium carbonate, potassium carbonate, sodium carbonate, cesium carbonate, etc.), alkali metal hydrocarbon salts (for example, lithium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.) , Salts of inorganic bases such as alkali metal hydroxides (for example, lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, etc.); for example, tri (lower) alkylamines (for example, trimethylamine, triethylamine, N- Ethyldiisopropylamine), pyridine, quinoline, piperidine, imidazole, pico , Dimethylaminopyridine, dimethylaniline, N- (lower) alkyl-morpholine (eg, N-methylmorpholine), 1,5-diazabicyclo [4.3.0] nonene-5 (DBN), 1,8- Salts of organic bases such as diazabicyclo [5.4.0] undecene-7 (DBU) and 1,4-diazabicyclo [2.2.2] octane (DABCO); hydrochloride, hydrobromide, hydrogen iodide Salts of inorganic acids such as acid salts, sulfates, nitrates, phosphates; formate, acetate, propionate, oxalate, malonate, succinate, fumarate, maleate, lactate And salts of organic acids such as malate, citrate, tartrate, carbonate, picrate, methanesulfonate, ethanesulfonate, p-toluenesulfonate, glutamate and the like.

  In addition, compounds in a form in which a solvate (eg, hydrate, ethanolate, etc.) is added to the raw materials and target compounds shown in each reaction formula are also included in each general formula. Preferred solvates include hydrates.

  Each target compound obtained in each of the above reaction formulas is obtained by cooling the reaction mixture, for example, separating the crude reaction product by an isolation operation such as filtration, concentration, extraction, etc., and performing column chromatography, recrystallization, etc. It can be isolated and purified from the reaction mixture by ordinary purification procedures.

  The compound represented by the general formula (1) of the present invention naturally includes isomers such as geometric isomers, stereoisomers, and optical isomers.

The following points should be noted regarding the compound of the general formula (1). That is, when the definition of R _{1 in} the general formula (1) is hydrogen, it includes a tautomer of a quinolone ring. That is, in the quinolone compound of the general formula (1), the formula (1 ′) in which R ₁ represents hydrogen.

[Wherein, R ₂ , R ₃ , R ₄ , R ₅ , R ₆ and R ₇ are the same as described above. ] Is a compound of the tautomer (1 ″)

[Wherein, R ₂ , R ₃ , R ₄ , R ₅ , R ₆ and R ₇ are the same as described above. ]. That is, the compounds represented by the formulas (1 ′) and (1 ″) are both in a tautomeric equilibrium state that can be represented by the following equilibrium formula.

[Wherein, R ₂ , R ₃ , R ₄ , R ₅ , R ₆ and R ₇ are the same as described above. ]
As described above, this type of tautomerism between 4-quinolone compounds and 4-hydroxyquinoline compounds is well known in the art, and both tautomers are in equilibrium and are in a state where they can be converted into each other. This will be apparent to those skilled in the art.

  Accordingly, the compound represented by the general formula (1) of the present invention naturally includes the above tautomers.

  In this specification, the structural formula of the 4-quinolone compound is used for the purpose of including such a tautomeric compound and the structural formula of the starting compound for convenience.

The present invention also provides the same isotope as the compound represented by the general formula (1) except that one or more atoms are replaced by one or more atoms having a specific atomic mass or mass number. Also includes body labeled compounds. Examples of isotopes that can be incorporated into the compounds of the present invention include hydrogen, carbon, nitrogen such as ² H, ³ H, ¹³ C, ¹⁴ C, ¹⁵ N, ¹⁸ O, ¹⁷ O, ¹⁸ F, ³⁶ Cl, respectively. Oxygen, sulfur, fluorine, and chlorine isotopes. Specific isotope-labeled compounds of the invention containing the above isotopes and / or other isotopes of other atoms, for example, compounds incorporating radioactive isotopes such as ³ H and ¹⁴ C, Useful in drug tissue distribution assays and / or matrix tissue distribution assays. Tritiated (ie, ³ H) and carbon-14 (ie, ¹⁴ C) isotopes are particularly preferred due to their ease of preparation and detectability. In addition, substitution with heavier isotopes such as deuterium (ie, ² H) provides certain therapeutic benefits resulting from improved metabolic stability, eg, increased in vivo half-life or reduced dosage requirements. Can be expected. The isotope-labeled compounds of the present invention are generally obtained by substituting non-isotopically labeled reagents with readily available isotope-labeled reagents by the methods disclosed in the above reaction schemes and / or examples below. Can be prepared.

  The compound of the general formula (1) and a salt thereof are used in the form of a general pharmaceutical preparation. The preparation is prepared by using diluents or excipients such as fillers, extenders, binders, moisturizers, disintegrants, surfactants, lubricants and the like that are usually used. Various forms of this pharmaceutical preparation can be selected according to the purpose of treatment. Representative examples thereof include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, injections ( Liquid, suspension, etc.).

  In molding into a tablet form, various carriers well known in the art can be widely used as carriers. Examples thereof include excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, water, ethanol, propanol, simple syrup, glucose solution, starch solution, Binders such as gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone, dry starch, sodium alginate, agar powder, laminaran powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, lauryl sulfate Disintegrators such as sodium, stearic acid monoglyceride, starch, lactose, disintegration inhibitors such as sucrose, stearin, cocoa butter, hydrogenated oil, absorption accelerators such as quaternary ammonium base, sodium lauryl sulfate, glyce Emissions, moisturizing agents such as starch, starch, lactose, kaolin, bentonite, adsorbent such as colloidal silicic acid, purified talc, stearates, boric acid powder, a lubricant such as polyethylene glycol can be used. Further, the tablets can be made into tablets with ordinary coatings as necessary, for example, sugar-coated tablets, gelatin-encapsulated tablets, enteric-coated tablets, film-coated tablets, double tablets, and multilayer tablets.

  When forming into the form of a pill, those conventionally known in this field can be widely used as the carrier. Examples include excipients such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, kaolin and talc, binders such as gum arabic powder, tragacanth powder, gelatin, ethanol, and disintegrants such as laminaran and agar. Can be used.

  In molding into a suppository form, conventionally known carriers can be widely used. Examples thereof include polyethylene glycol, cocoa butter, higher alcohols, higher alcohol esters, gelatin, semi-synthetic glycerides and the like.

  Capsules are usually prepared by mixing the active ingredient compound with the various carriers exemplified above and filling them into hard gelatin capsules, soft capsules and the like according to conventional methods.

  When prepared as injections, solutions, emulsions and suspensions are preferably sterilized and isotonic with blood, and are commonly used in this field as diluents when molded into these forms For example, water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters and the like can be used.

  In this case, a sufficient amount of sodium chloride, glucose or glycerin may be contained in the pharmaceutical preparation to prepare an isotonic solution, and a normal solubilizing agent, buffering agent, soothing agent, etc. may be added. May be. Further, if necessary, a colorant, a preservative, a flavoring agent, a sweetening agent, and other pharmaceuticals may be contained in the pharmaceutical preparation.

  The amount of the compound of the general formula (1) or a salt thereof to be contained in the pharmaceutical preparation of the present invention is not particularly limited and is appropriately selected from a wide range, but is usually about 0.1 to 70 in the preparation composition. % By weight, preferably about 0.1 to 30% by weight.

  The administration method of the pharmaceutical preparation of the present invention is not particularly limited, and it is administered by a method according to various preparation forms, patient age, sex and other conditions, disease degree, and the like. For example, in the case of tablets, pills, solutions, suspensions, emulsions, granules and capsules, they are administered orally. In the case of an injection, it is administered intravenously alone or mixed with a normal replacement fluid such as glucose and amino acids, and further administered alone intramuscularly, intradermally, subcutaneously or intraperitoneally as necessary. In the case of a suppository, it is administered intrarectally.

  The dosage of the pharmaceutical preparation of the present invention is appropriately selected depending on the usage, the patient's age, sex and other conditions, the degree of disease, etc., but the amount of the active ingredient compound is usually about 0.1 to 0.1 kg / kg body weight per day. It should be about 10 mg. In addition, the active ingredient compound is desirably contained in the dosage unit form in a range of about 1 to 200 mg.

  The compound of the present invention could not be obtained by conventional therapies by administering in combination with L-dopa preparations, dopamine receptor agonists, dopamine metabolizing enzyme inhibitors, dopamine release accelerators, central anticholinergic agents, etc. Effects such as dose reduction, side effect improvement, and therapeutic effect enhancement can be obtained.

  Since the compound of the present invention has a mitochondrial function protection improving action, a nerve cell protection and a function repair action, etc., it treats neurodegenerative diseases, diseases associated with impaired nerve function, diseases associated with decreased mitochondrial function, Effective for prevention.

  Neurodegenerative diseases include Parkinson's disease, Parkinson's syndrome, juvenile parkinsonism, striatal nigra degeneration, progressive supranuclear paralysis, pure ataxia, Alzheimer's disease, Pick's disease, prion disease, basal ganglia Degenerative disease, diffuse Lewy body disease, Huntington's disease, spiny erythroid chorea, benign hereditary chorea, paroxysmal choreoathetosis, essential tremor, essential myoclonus, Gilles de la Tourette syndrome, Rett syndrome , Degenerative balism, deformed muscular dystonia, athetosis, spastic torticollis, mage syndrome, cerebral palsy, Wilson disease, Segawa disease, Hallelfolden spats syndrome, neuroaxonal dystrophy, pallidal atrophy, spinocerebellar degeneration , Cortical cerebellar atrophy, Holmes cerebellar atrophy, olive bridge cerebellar atrophy, hereditary olive bridge cerebellar atrophy, Joseph's disease, dentate nucleus Nucleus Ryukyu atrophy, Gerstmann-Stroisler-Scheinka syndrome, Friedreich ataxia, Lucy-Levy syndrome, May-White syndrome, congenital cerebellar ataxia, periodic hereditary ataxia, telangiectasia Ataxia, amyotrophic lateral sclerosis, progressive bulbar palsy, spinal progressive amyotrophy, bulbospinal muscular atrophy, Weldnig-Hoffmann disease, Kugelberg-Wehlander disease, hereditary spastic paraplegia, spinal cavity Symptom, syringomyelia, Arnold Kiary malformation, stiff man syndrome, Klippel file syndrome, phathiorond disease, hypomyelopathy, dandy walker syndrome, spina bifida, schughren-larson syndrome, radiation myelopathy, age-related macular degeneration , Stroke (eg, cerebral infarction, cerebral hemorrhage, etc.) and / or associated dysfunction or neuroprolapse It includes symptoms.

  Diseases associated with impaired neurological function include spinal cord injury, chemotherapy-induced neuropathy, diabetic neuropathy, radioactive disorders, demyelinating diseases (eg, multiple sclerosis, acute disseminated encephalomyelitis, transverse spinal cord) Inflammation, progressive multifocal leukoencephalopathy, subacute sclerosis panencephalitis, chronic inflammatory demyelinating polyradiculoneuritis, Guillain-Barre syndrome, etc.).

  Diseases associated with reduced mitochondrial function include Pearson's syndrome, diabetes, hearing loss, malignant migraine, Leber's disease, MELAS, MARF, MERRF, MARF / Melas duplication syndrome, NARP, pure myopathy, mitochondrial cardiomyopathy, Myopathy, dementia, gastrointestinal ataxia, acquired ironblastic anemia, aminoglycoside-induced hearing loss, complex III deficiency due to cytochrome b gene mutation, symmetric multiple lipomatosis, ataxia, myoclonus, retinopathy, MNGIE, ANT1 abnormality, Twinkle abnormality, POLG abnormality, repetitive myoglobinuria, SANDO, ARCO, complex I deficiency, complex II deficiency, optic nerve atrophy, complex IV deficiency severe infant type, mitochondrial DNA deficiency syndrome, Leigh encephalopathy, chronic progressive extraocular palsy syndrome (CPEO), Keynes-Sayer syndrome, encephalopathy, lactic acidemia, myoglobinuria, drug-induced mito Undria disease, schizophrenia, major depressive disorder, bipolar type I disorder, bipolar type II disorder, mixed state, dysthymic disorder, atypical depression, seasonal emotional disorder, postpartum depression, mild depression, repetitive Sexual short-term depressive disorder, refractory depression, chronic depression, double depression, acute renal failure.

  Furthermore, the compounds of the present invention may be used for ischemic heart disease and / or dysfunction associated therewith, heart failure, cardiomyopathy, aortic dissection, immunodeficiency, autoimmune disease, pancreatic failure, diabetes, atheroembolic kidney disease, multiple cysts Kidney, medullary cystic disease, renal cortical necrosis, malignant nephrosclerosis, renal failure, hepatic encephalopathy, liver failure, chronic obstructive pulmonary disease, pulmonary embolism, bronchiectasis, silicosis, black lung, idiopathic pulmonary fiber It is effective for the treatment and / or prevention of diseases such as symptom, Stevens-Johnson syndrome, toxic epidermal necrosis, muscular dystrophy, clostridial muscular necrosis and femoral condyle osteonecrosis.

  The compounds of the present invention include L-dopa preparations, dopamine receptor agonists, dopamine metabolizing enzyme inhibitors, dopamine release promoters, central anticholinergic agents or cholinesterase inhibitors, glutamate N-methyl-D-aspartate receptor antagonists Or administration in combination with drugs used for thrombolytic therapy, anti-cerebral edema therapy, cerebral protection therapy, anti-thrombotic therapy and plasma dilution therapy, reduced dosage, improved side effects, Effects such as enhanced therapeutic effects can be obtained.

  Hereinafter, the present invention will be further clarified with reference examples, examples, and pharmacological test examples.

Reference example 1
N-cyclohexyl-4-fluoro-2-nitro-N-methylaniline
To a solution (20 ml) of 5.0 g (31.4 mmol) of 2,5-difluoronitrobenzene in 20 ml of N-methylpyrrolidone (NMP), 6.0 g (43.5 mmol) of potassium carbonate and 4.6 g of N-methylcyclohexylamine (40 g) .6 mmol) was added and the mixture was stirred at 100 ° C. for 3 hours. The reaction was cooled to room temperature, water was added, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The obtained dried product was concentrated under reduced pressure to obtain 7.0 g (yield 89%) of N-cyclohexyl-4-fluoro-2-nitro-N-methylaniline as a yellow oil.
¹ H-NMR (CDCl ₃ ) δppm: 1.12-1.80 (10H, m), 2.67 (3H, s), 3.00-3.09 (1H, m), 7.07-7.20 (2H, m), 7.42-7.47 (1H, m).

  The compounds of Reference Examples 2 to 5 below were produced in the same manner as in Reference Example 1 using appropriate starting materials.

Reference example 2
4-Fluoro-N- (2-methoxyethyl) -N-methyl-2-nitroaniline
¹ H-NMR (CDCl ₃ ) δppm: 2.85 (3H, s), 3.25−3.31 (5H, m), 3.52 (2H, t, J = 5.6 Hz), 7.16−7.20 (2H, m), 7.43−7.47 (1H, m).

Reference example 3
4-Fluoro-N-isobutyl-N-methyl-2-nitroaniline
¹ H-NMR (CDCl ₃ ) δppm: 0.89 (3H, s), 0.91 (3H, s), 1.89-1.98 (1H, m), 2.81 (3H, s), 2.92 (2H, d, J = 7.5 Hz ), 7.15-7.20 (2H, m), 7.42-7.46 (1H, m).

Reference example 4
4-Fluoro-N-isopropyl-N-methyl-2-nitroaniline
¹ H-NMR (CDCl ₃ ) δppm: 1.16 (3H, s), 1.19 (3H, s), 2.67 (3H, s), 3.50-3.61 (1H, m), 7.15-7.20 (2H, m), 7.43 -7.46 (1H, m).

Reference Example 5
4-Fluoro-N-methyl-2-nitro-N-propylaniline
¹ H-NMR (CDCl ₃ ) δppm: 0.84 (3H, t, J = 7.5 Hz), 1.51-1.66 (2H, m), 2.77 (3H, s), 3.00 (2H, t, J = 7.5 Hz), 7.05-7.20 (2H, m), 7.44 (1H, dd, J = 2.75 Hz, J = 8.0 Hz).

Reference Example 6
4-Fluoro-2-nitro-1-propylsulfanylbenzene
To a solution (15 ml) of 5.0 g (31.4 mmol) of 2,5-difluoronitrobenzene in 15 ml of N-methylpyrrolidone (NMP), 5.0 g (36.2 mmol) of potassium carbonate and 2.7 g (35. 5 mmol) was added and the mixture was stirred at 90 ° C. for 2 h. The reaction solution was cooled to room temperature, water (50 ml) was added, and the reaction product was extracted with ethyl acetate (100 ml). The organic layer was washed with water and then dried over anhydrous magnesium sulfate. The obtained dried product was concentrated to dryness under reduced pressure to obtain 6.7 g (99% yield) of 4-fluoro-2-nitro-1-propylsulfanylbenzene as a yellow powder.
¹ H-NMR (CDCl ₃ ) δppm: 1.06 (3H, t, J = 7.5 Hz), 1.68−1.83 (2H, m), 2.89 (2H, t, 7.5 Hz), 7.27−7.42 (2H, m), 7.89 (2H, dd, J = 2.75 Hz, J = 8.5 Hz).

Reference Example 7
1-tert-Butoxy-4-fluoro-2-nitrobenzene Potassium tert-butoxide 3.55 g (31.6 mmol) in tetrahydrofuran (THF) (20 ml) was cooled in a methanol-ice bath and further 2,5-difluoro 4.2 g (26.4 mmol) of nitrobenzene was added. The mixture was warmed to room temperature, stirred for 96 hours, and further stirred at 60 ° C. for 1 hour. Under cooling in an ice water bath, 2 ml of water and 2 ml of 2N-hydrochloric acid were added to the reaction solution, and then water was added. The resulting mixture was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 19: 1). The purified product was concentrated under reduced pressure to obtain 4.5 g (yield 80%) of 1-tert-butoxy-4-fluoro-2-nitrobenzene as an orange oil.
¹ H-NMR (CDCl ₃ ) δ ppm: 1.38 (9H, s), 7.18-7.20 (2H, m), 7.47 (1H, d, J = 7.1 Hz).

Reference Example 8
4-Fluoro-2-nitro-1-propoxybenzene
To a solution of 3.3 g (21.0 mmol) of 4-fluoro-2-nitrophenol in N, N-dimethylformamide (DMF) (7 ml), 3.48 g (25.2 mmol) of potassium carbonate and 1-iodopropane 3. 95 g (23.2 mmol) of DMF solution (3 ml) was added and the mixture was stirred at room temperature for 48 hours. Water was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed twice with saturated brine and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 9: 1). The purified product was concentrated under reduced pressure to obtain 4.03 g (yield 96%) of 4-fluoro-2-nitro-1-propoxybenzene as a yellow oily substance.
¹ H-NMR (CDCl ₃ ) δppm: 1.06 (3H, t, J = 7.4Hz), 1.78-1.92 (2H, m), 4.04 (2H, t, J = 6.4Hz), 7.04 (1H, dd, J = 4.3 Hz, J = 9.2 Hz), 7.21-7.29 (1H, m), 7.58 (1H, dd, J = 3.1 Hz, J = 7.8 Hz).

  The compounds of Reference Examples 9 to 16 below were produced in the same manner as in Reference Examples 7 to 8 using appropriate starting materials.

Reference Example 9
4-Fluoro-1-isopropoxy-2-nitrobenzene
¹ H-NMR (CDCl ₃ ) δ ppm: 1.36 (3H, s), 4.54−4.63 (1H, m), 7.02−7.05 (1H, m), 7.18−7.26 (1H, m), 7.49 (1H, dd, J = 3.0 Hz, J = 7.5 Hz).

Reference Example 10
1-Ethoxy-4-fluoro-2-nitrobenzene
¹ H-NMR (CDCl ₃ ) δppm: 1.44 (3H, t, J = 7.0 Hz), 4.08 (2H, q, J = 7.0 Hz), 7.02 (1H, dd, J = 4.25 Hz, J = 9.25 Hz) , 7.22-7.30 (1H, m), 7.56 (1H, dd, J = 3.25 Hz, J = 7.75 Hz).

Reference Example 11
1-cyclopropylmethoxy-4-fluoro-2-nitrobenzene
¹ H-NMR (CDCl ₃ ) δppm: 0.36−0.41 (2H, m), 0.61−0.69 (2H, m), 1.22-1.28 (1H, m), 3.95 (2H, d, J = 6.8 Hz), 7.04 (1H, dd, J = 4.4 Hz, J = 9.2 Hz), 7.20-7.27 (1H, m), 7.57 (1H, dd, J = 3.1 Hz, J = 7.8 Hz).

Reference Example 12
4-Fluoro-2-nitro-1- (4,4,4-trifluorobutoxy) benzene
¹ H-NMR (CDCl ₃ ) δppm: 2.04−2.16 (2H, m), 2.31−2.44 (2H, m), 4.14 (2H, t, J = 5.9 Hz), 7.04 (1H, dd, J = 4.3 Hz) , J = 9.2Hz), 7.24-7.32 (1H, m), 7.61 (1H, dd, J = 3.2 Hz, J = 7.8 Hz).

Reference Example 13
4-Fluoro-1- (2-methoxyethoxy) -2-nitrobenzene
¹ H-NMR (CDCl ₃ ) δppm: 3.45 (3H, s), 3.78 (2H, t, J = 4.8Hz), 4.24 (2H, t, J = 4.8Hz), 7.12 (1H, dd, J = 4.4 Hz, J = 9.2Hz), 7.23-7.30 (1H, m), 7.59 (1H, dd, J = 3.1 Hz, J = 7.8 Hz).

Reference Example 14
1-cyclopentyloxy-4-fluoro-2-nitrobenzene
¹ H-NMR (CDCl ₃ ) δppm: 1.62-1.66 (2H, m), 1.83-1.94 (6H, m), 4.82-4.86 (1H, m), 7.04 (1H, dd, J = 4.4 Hz, J = 9.3Hz), 7.19-7.27 (1H, m), 7.54 (1H, dd, J = 3.2 Hz, J = 7.8 Hz).

Reference Example 15
1-cyclobutylmethoxy-4-fluoro-2-nitrobenzene
¹ H-NMR (CDCl ₃ ) δppm: 1.90−2.02 (4H, m), 2.08−2.15 (2H, m), 2.77−2.81 (1H, m), 4.03 (2H, d, J = 6.2 Hz), 7.04 (1H, dd, J = 4.3 Hz, J = 9.2 Hz), 7.21-7.28 (1H, m), 7.58 (1H, dd, J = 3.1 Hz, J = 7.8 Hz).

Reference Example 16
2- (4-Fluoro-2-nitrophenoxymethyl) tetrahydrofuran
¹ H-NMR (CDCl ₃ ) δppm: 1.88−2.12 (4H, m), 3.80−3.94 (2H, m), 4.11 (2H, d, J = 4.0 Hz), 4.27−4.32 (1H, m), 7.10 (1H, dd, J = 4.4 Hz, J = 9.3 Hz), 7.22-7.30 (1H, m), 7.59 (1H, dd, J = 3.1 Hz, J = 7.8 Hz).

Reference Example 17
2- [3- (4-Fluoro-2-nitrophenoxy) propyl] isoindole-1,3-dione
To a solution (80 ml) of N-N-dimethylformamide (DMF) in 6.0 g (38.2 mmol) of 4-fluoro-2-nitrophenol was added 10.8 g (78.1 mmol) of potassium carbonate and N- (3-bromo 12.1 g (45.1 mmol) of propyl) phthalimide was added and the mixture was stirred at 60 ° C. for 4 hours. The reaction solution was cooled to room temperature, 200 ml of water was added and ice-cooled. The precipitated insoluble material was collected by filtration. The filtrate was washed with water (50 ml × 3) and then air-dried to give pale yellow powder of 2- [3- (4-fluoro-2-nitrophenoxy) propyl] isoindole-1,3-dione (13.2 g). Yield 100%).
¹ H-NMR (CDCl ₃ ) δppm: 2.18-2.28 (2H, m), 3.93 (2H, t, J = 6.5Hz), 4.15 (2H, t, J = 6.0Hz), 7.04 (1H, dd, J = 4.3 Hz, J = 9.2Hz), 7.23−7.28 (1H, m), 7.58 (1H, dd, J = 3.1 Hz, J = 7.8Hz), 7.69−7.74 (2H, m), 7.81−7.85 (2H , m).

Reference Example 18
3- (4-Fluoro-2-nitrophenoxy) propylamine
6.5 g of 2- [3- (4-fluoro-2-nitrophenoxy) propyl] isoindole-1,3-dione is suspended in 140 ml of ethanol, and 3.0 ml of hydrazine hydrate is added to the resulting suspension. The mixture was stirred under reflux with heating for 3.5 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. To the residue was added 13 ml of 5N aqueous sodium hydroxide solution, and the resulting mixture was extracted with dichloromethane. The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The obtained dried product was concentrated under reduced pressure to obtain 4.03 g (yield: 100%) of 3- (4-fluoro-2-nitrophenoxy) propylamine as a red-orange oily substance.
¹ H-NMR (CDCl ₃ ) δppm: 1.92−2.02 (2H, m), 2.94 (2H, t, J = 6.5 Hz), 4.19 (2H, t, J = 5.9 Hz), 7.07 (1H, dd, J = 4.3 Hz, J = 9.2 Hz), 7.22-7.30 (1H, m), 7.59 (1H, dd, J = 3.1 Hz, J = 7.8 Hz).

Reference Example 19
N- [3- (4-Fluoro-2-nitrophenoxy) propyl] acetamide
To a dichloromethane solution of 2.0 g (9.33 mmol) of 3- (4-fluoro-2-nitrophenoxy) propylamine was added 1.5 ml (18.6 mmol) of pyridine and 0.97 g (10.3 mmol) of acetic anhydride under ice cooling. Mmol) and 4 ml additional dichloromethane. The resulting mixture was stirred at room temperature for 15 hours. 9.5 ml of 2N hydrochloric acid was added to the reaction solution, and the mixture was stirred. Water was added to the mixture after stirring, and the resulting mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, then concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1 → 20: 1). The purified product was concentrated under reduced pressure to obtain 2.13 g (yield 89%) of N- [3- (4-fluoro-2-nitrophenoxy) propyl] acetamide as a yellow oil.
¹ H-NMR (CDCl ₃ ) δppm: 2.04 (3H, s), 2.03−2.12 (2H, m), 3.48−3.55 (2H, m), 4.20 (2H, t, J = 5.5 Hz), 6.56 (1H brs), 7.08 (1H, dd, J = 4.3 Hz, J = 9.3 Hz), 7.26-7.36 (1H, m), 7.70 (1H, dd, J = 3.2 Hz, J = 7.8 Hz).

Reference Example 20
N- [3- (4-Fluoro-2-nitrophenoxy) propyl] methanesulfonamide
To a solution of 2.0 g (9.33 mmol) of 3- (4-fluoro-2-nitrophenoxy) propylamine in dichloromethane was added 1.5 ml (18.6 mmol) of pyridine and 0.8 ml (10 ml of methanesulfonyl chloride) under ice cooling. .3 mmol) and 4 ml of dichloromethane was added. The resulting mixture was stirred at room temperature for 24 hours, 0.12 ml (1.5 mmol) of methanesulfonyl chloride was further added, and the mixture was stirred at room temperature for 15 hours. 9.5 ml of 2N hydrochloric acid was added to the reaction solution, and the mixture was stirred. Water was added to the mixture after stirring, and the resulting mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, then concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 4: 1 → 1: 1). The purified product was concentrated under reduced pressure to obtain 1.2 g (44% yield) of N- [3- (4-fluoro-2-nitrophenoxy) propyl] methanesulfonamide as a yellow-orange oil.
¹ H-NMR (CDCl ₃ ) δppm: 2.09−2.18 (2H, m), 3.00 (3H, s), 3.39−3.46 (2H, m), 4.23 (2H, t, J = 5.6 Hz), 5.00 (1H brs), 7.09 (1H, dd, J = 4.3 Hz, J = 9.2 Hz), 7.26-7.35 (1H, m), 7.66 (1H, dd, J = 3.1 Hz, J = 7.8 Hz).

Reference Example 21
[3- (4-Fluoro-2-nitrophenoxy) propyl] carbamic acid phenyl ester
To a dioxane solution (43 ml) of 4.03 g (18.8 mmol) of 3- (4-fluoro-2-nitrophenoxy) propylamine, 2.90 ml (21.4 mmol) of triethylamine and phenyl 2 .52 ml (20.0 mmol) was added and the mixture was stirred at room temperature for 0.5 hour. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane: ethyl acetate = 30: 1). The purified product was concentrated to dryness under reduced pressure to obtain 5.92 g (yield 94%) of [3- (4-fluoro-2-nitrophenoxy) propyl] carbamic acid phenyl ester as a yellow powder.
¹ H-NMR (CDCl ₃ ) δppm: 2.09−2.18 (2H, m), 3.48−3.56 (2H, m), 4.21 (2H, t, J = 5.7 Hz), 5.69 (1H, brs), 7.05−7.20 (4H, m), 7.26-7.37 (3H, m), 7.65 (1H, dd, J = 3.1 Hz, J = 7.8 Hz).

Reference Example 22
3- [3- (4-Fluoro-2-nitrophenoxy) propyl] -1,1-dimethylurea [3- (4-fluoro-2-nitrophenoxy) propyl] carbamic acid phenyl ester 5.89 g (17.6) Mmol) in DMF (25 ml) was added 2.5 ml of 50% aqueous dimethylamine and the mixture was stirred at room temperature for 24 hours. Water was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed twice with saturated brine and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane: ethyl acetate = 19: 1 → 4: 1 → 2: 1). The purified product was concentrated to dryness under reduced pressure to give 4.10 g (yield 82%) of 3- [3- (4-fluoro-2-nitrophenoxy) propyl] -1,1-dimethylurea as a pale yellow oil. Obtained.
¹ H-NMR (CDCl ₃ ) δppm: 2.03−2.12 (2H, m), 2.89 (6H, s), 3.42−3.49 (2H, m), 4.17 (2H, t, J = 5.8 Hz), 4.85 (1H brs), 7.09 (1H, dd, J = 4.3 Hz, J = 9.3 Hz), 7.24-7.32 (1H, m), 7.61 (1H, dd, J = 3.2 Hz, J = 7.8 Hz).

Reference Example 23
1- [3- (4-Fluoro-2-nitrophenoxy) propyl] -1,3,3-trimethylurea
Sodium hydride (55%) was added to a DMF solution (9 ml) of 2.0 g (7.0 mmol) of 3- [3- (4-fluoro-2-nitrophenoxy) propyl] -1,1-dimethylurea under ice cooling. (Oil) 396 mg (9.1 mmol) was added and the mixture was stirred at room temperature for 5 min. To the stirred mixture, 0.735 ml (11.8 mmol) of methyl iodide was added and the resulting mixture was stirred at room temperature for 48 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane: ethyl acetate = 9: 1 → 6: 1). The purified product was concentrated under reduced pressure to obtain 0.83 g (yield 40%) of 1- [3- (4-fluoro-2-nitrophenoxy) propyl] -1,3,3-trimethylurea as a pale yellow oil. Obtained.
¹ H-NMR (CDCl ₃ ) δppm: 2.04−2.14 (2H, m), 2.76 (6H, s), 2.83 (3H, s), 3.38 (2H, t, J = 6.9Hz), 4.09 (2H, t , J = 5.9Hz), 7.04 (1H, dd, J = 4.3 Hz, J = 9.3Hz), 7.22-7.30 (1H, m), 7.60 (1H, dd, J = 3.1 Hz, J = 7.7 Hz).

Reference Example 24
5-Fluoro-2-propoxyaniline
2.0 g (10.0 mmol) of 4-fluoro-2-nitro-1-propoxybenzene and 750 mg of 5% palladium carbon were added to 30 ml of ethanol and subjected to catalytic reduction at room temperature and normal pressure. The catalyst was removed by celite filtration, and the filtrate was concentrated under reduced pressure. The residue was dissolved in dichloromethane and dried over anhydrous magnesium sulfate. The obtained dried product was concentrated under reduced pressure to obtain 1.45 g (yield 86%) of 5-fluoro-2-propoxyaniline as a red-orange oily substance.
¹ H-NMR (CDCl ₃ ) δppm: 1.04 (3H, t, J = 7.4Hz), 1.74−1.88 (2H, m), 3.89 (2H, brs), 3.90 (2H, t, J = 6.5Hz), 6.31-6.46 (2H, m), 6.66 (1H, dd, J = 5.1 Hz, J = 8.7 Hz).

  The compounds of Reference Examples 25 to 42 below were produced in the same manner as in Reference Example 24 using appropriate starting materials.

Reference Example 25
5-Fluoro-2-isopropoxyaniline
¹ H-NMR (CDCl ₃ ) δppm: 1.32 (3H, s), 1.35 (3H, s), 3.88 (2H, brs), 4.38-4.48 (1H, m), 6.31-6.46 (2H, m), 6.68 −6.73 (1H, m).

Reference Example 26
2-Ethoxy-5-fluoroaniline
¹ H-NMR (CDCl ₃ ) δppm: 1.39 (3H, t, J = 7.0 Hz), 3.90 (2H, brs), 3.97 (2H, q, J = 7.0 Hz), 6.31-6.46 (2H, m), 6.63-6.68 (1H, m).

Reference Example 27
5-Fluoro-2-morpholin-4-ylaniline
¹ H-NMR (CDCl ₃ ) δppm: 2.83 (4H, t, J = 4.6 Hz), 3.81 (4H, t, J = 4.6 Hz), 4.13 (2H, brs), 6.38-6.45 (2H, m), 6.93-6.97 (1H, m).

Reference Example 28
5-Fluoro-2-pyrrolidin-1-ylaniline
¹ H-NMR (CDCl ₃ ) δppm: 1.88-1.94 (4H, m), 2.94-3.00 (4H, m), 4.03 (2H, brs), 6.35-6.46 (2H, m), 6.90-6.95 (1H, m).

Reference Example 29
2-Cyclopropylmethoxy-5-fluoroaniline
¹ H-NMR (CDCl ₃ ) δppm: 0.29-0.35 (2H, m), 0.58-0.65 (2H, m), 1.22-1.29 (1H, m), 3.77 (2H, d, J = 6.9Hz), 3.94 (2H, brs), 6.29-6.46 (2H, m), 6.64 (1H, dd, J = 5.1 Hz, J = 8.8 Hz).

Reference Example 30
N ¹ -cyclohexyl-4-fluoro-N ¹ -methylbenzene-1,2-diamine
¹ H-NMR (CDCl ₃ ) δppm: 1.11-1.31 (4H, m), 1.55-1.82 (6H, m), 2.57-2.68 (4H, m), 4.18 (2H, brs), 6.33-6.44 (2H, m), 6.92-6.98 (1H, m).

Reference Example 31
4-Fluoro-N ^1- (2-methoxyethyl) -N ¹ -methylbenzene-1,2-diamine
¹ H-NMR (CDCl ₃ ) δppm: 2.70 (3H, s), 2.96 (2H, t, J = 5.4 Hz), 3.39 (3H, s), 3.45 (2H, t, J = 5.4 Hz), 4.38 ( 2H, brs), 6.33-6.43 (2H, m), 6.93-6.99 (1H, m).

Reference Example 32
4-Fluoro-N ¹ -isobutyl-N ¹ -methylbenzene-1,2-diamine
¹ H-NMR (CDCl ₃ ) δppm: 0.92 (3H, s), 0.94 (3H, s), 1.62-1.83 (1H, m), 2.54-2.60 (5H, m), 6.30-6.49 (2H, m) , 6.82-6.93 (1H, m).

Reference Example 33
4-Fluoro-N ¹ -isopropyl-N ¹ -methylbenzene-1,2-diamine
¹ H-NMR (CDCl ₃ ) δppm: 1.05 (3H, s), 1.07 (3H, s), 2.55 (3H, s), 3.06−3.17 (1H, m), 4.16 (2H, brs), 6.34−6.45 (2H, m), 6.91-6.97 (1H, m).

Reference Example 34
4-Fluoro-N ¹ -methyl-N ¹ -propylbenzene-1,2-diamine
¹ H-NMR (CDCl ₃ ) δppm: 0.86 (3H, t, J = 7.4 Hz), 1.41-1.56 (2H, m), 2.57 (3H, s), 2.72 (2H, t, J = 7.25 Hz), 4.18 (2H, brs), 6.35-6.44 (2H, m), 6.91-6.97 (1H, m).

Reference Example 35
N- [3- (2-Amino-4-fluorophenoxy) propyl] acetamide
¹ H-NMR (CDCl ₃ ) δppm: 1.95−2.05 (2H, m), 1.97 (3H, s), 3.42−3.50 (2H, m), 3.92 (2H, brs), 4.02 (2H, t, J = 5.9Hz), 5.83 (1H, brs), 6.32-6.47 (2H, m), 6.68 (1H, dd, J = 5.0 Hz, J = 8.8 Hz).

Reference Example 36
N- [3- (2-Amino-4-fluorophenoxy) propyl] methanesulfonamide
¹ H-NMR (CDCl ₃ ) δppm: 2.02−2.11 (2H, m), 2.94 (3H, s), 3.33−3.40 (2H, m), 3.91 (2H, brs), 4.07 (2H, t, J = 5.7Hz), 4.76 (1H, brs), 6.32-6.46 (2H, m), 6.68 (1H, dd, J = 5.0 Hz, J = 8.8 Hz).

Reference Example 37
5-Fluoro-2- (4,4,4-trifluorobutoxy) aniline
¹ H-NMR (CDCl ₃ ) δppm: 2.01−2.12 (2H, m), 2.22−2.41 (2H, m), 3.87 (2H, brs), 4.01 (2H, t, J = 6.0Hz), 6.32−6.47 (2H, m), 6.65 (1H, dd, J = 5.0 Hz, J = 8.8 Hz).

Reference Example 38
1- [3- (2-Amino-4-fluorophenoxy) propyl] -1,3,3-trimethylurea
¹ H-NMR (CDCl ₃ ) δppm: 1.99-2.10 (2H, m), 2.78 (6H, s), 2.84 (3H, s), 3.37 (2H, t, J = 6.9Hz), 3.94 (2H, brs ), 3.97 (2H, t, J = 6.1 Hz), 6.30-6.45 (2H, m), 6.65 (1H, dd, J = 5.1 Hz, J = 8.8 Hz).

Reference Example 39
5-Fluoro-2- (2-methoxyethoxy) aniline
¹ H-NMR (CDCl ₃ ) δppm: 3.43 (3H, s), 3.70-3.73 (2H, m), 3.99 (2H, brs), 4.07-4.10 (2H, m), 6.30-6.45 (2H, m) 6.72 (1H, dd, J = 5.1 Hz, J = 8.7 Hz).

Reference Example 40
2-Cyclopentyloxy-5-fluoroaniline
¹ H-NMR (CDCl ₃ ) δppm: 1.56-1.66 (2H, m), 1.75-1.87 (6H, m), 3.85 (2H, brs), 4.69-4.72 (1H, m), 6.30-6.45 (2H, m), 6.66 (1H, dd, J = 5.1 Hz, J = 8.8 Hz).

Reference Example 41
2-Cyclobutylmethoxy-5-fluoroaniline
¹ H-NMR (CDCl ₃ ) δppm: 1.86-1.96 (4H, m), 2.08-2.16 (2H, m), 2.74-2.80 (1H, m), 3.90 (2H, brs), 3.91 (2H, d, J = 6.7Hz), 6.31-6.45 (2H, m), 6.66 (1H, dd, J = 5.1 Hz, J = 8.8 Hz).

Reference Example 42
2-tert-Butoxy-5-fluoroaniline
¹ H-NMR (CDCl ₃ ) δ ppm: 1.37 (9H, s), 3.87 (2H, brs), 6.27-6.45 (2H, m), 6.85 (1H, dd, J = 5.6 Hz, J = 8.8 Hz).

Reference Example 43
5-Fluoro-2-propylsulfanylaniline
6.7 g (31.1 mmol) of 4-fluoro-2-nitro-1-propylsulfanylbenzene was dissolved in a mixed solvent of 40 ml of ethanol and 4 ml of water, and 17 g (0.32 mol) of ammonium chloride was added to the resulting mixture. Zinc powder 20g (0.31 mol) was added in small portions. The resulting mixture was stirred at room temperature for 1 hour. Insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain 5.8 g (yield 93%) of 5-fluoro-2-propylsulfanylaniline as a brown oily substance.
¹ H-NMR (CDCl ₃ ) δppm: 0.96 (3H, t, J = 7.3 Hz), 1.49−1.64 (2H, m), 2.62 (2H, t, J = 7.4 Hz), 4.51 (2H, brs), 6.35-6.47 (2H, m), 7.32-7.38 (1H, m).

Reference Example 44
4,5-difluoro-2-propoxyaniline 1-bromo-4,5-difluoro-2-propoxybenzene 3.0 g (11.9 mmol) in a toluene solution (60 ml) 2.38 g (13.1 mmol) benzophenone imine ) In toluene (20 ml), 275 mg (0.3 mmol) of tris (dibenzylideneacetone) dipalladium, 347 mg (0.6 mmol) of 9,9-dimethyl-4,5-bis (diphenylphosphino) xanthene (XANTPHOS) ) And 5.83 g (17.9 mmol) of cesium carbonate, and the mixture was stirred at 100 ° C. for 23 hours under a nitrogen atmosphere. The reaction solution was cooled to room temperature, water and saturated aqueous ammonium chloride were added, and the resulting mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in 60 ml of diethyl ether, and 10 ml of concentrated hydrochloric acid was added to the resulting solution and stirred for 2 hours. The reaction solution was adjusted to pH˜11 by adding 24 ml of 5N aqueous sodium hydroxide solution and concentrated under reduced pressure. The residue was dissolved in dichloromethane and washed with saturated brine. The organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 9: 1). The purified product was concentrated under reduced pressure to obtain 850 mg (yield 38%) of 4,5-difluoro-2-propoxyaniline as a brown oil.
¹ H-NMR (CDCl ₃ ) δppm: 1.04 (3H, t, J = 7.4Hz), 1.75-1.86 (2H, m), 3.71 (2H, brs), 3.88 (2H, t, J = 6.5Hz), 6.51 (1H, dd, J = 8.0Hz, 11.5Hz), 6.60 (1H, dd, J = 7.3 Hz, J = 11.8Hz).

Reference Example 45
1- (2-amino-4-fluorobenzoyl) pyrrolidine 4-fluoroanthranilic acid 2.0 g (12.8 mmol) in DMF solution (4 ml) and pyrrolidine 1.93 g (27.1 mmol) in DMF solution (4 ml) , 3.79 g (37.5 mmol) of triethylamine (4 ml), 3.11 g (23.0 mmol) of 1-hydroxybenzotriazole (HOBt) and 1- (3-dimethylaminopropyl) -3 -3.91 g (20.4 mmol) of ethylcarbodiimide hydrochloride (WSC) were added sequentially and the mixture was stirred at room temperature for 14 hours. Water was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1). The purified product was concentrated under reduced pressure to obtain 1.65 g (yield 62%) of 1- (2-amino-4-fluorobenzoyl) pyrrolidine as an orange oil.
¹ H-NMR (CDCl ₃ ) δppm: 1.75−2.00 (4H, m), 3.40−3.75 (4H, m), 4.85 (2H, brs), 6.33−6.40 (2H, m), 7.14−7.21 (1H, m).

Reference Example 46
α- (Hydroxymethylene) -4-methoxyphenylacetic acid ethyl ester 4-methoxyphenylacetic acid ethyl ester 2.0 g (10.3 mmol) in benzene solution (10 ml) under ice-cooling, sodium hydride (60% oily) 467 mg (11.7 mmol) was added and the mixture was stirred at room temperature for 5 minutes. The mixture after stirring was ice-cooled again, 1.02 ml (12.6 mmol) of ethyl formate was added, and the mixture was stirred at room temperature for 3 hours. Under ice cooling, water and ethyl acetate were added to the reaction solution, and then 6 ml of 2N hydrochloric acid was added to separate the layers. The organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 4: 1). The purified product was concentrated under reduced pressure to obtain 1.97 g (yield 86%) of α- (hydroxymethylene) -4-methoxyphenylacetic acid ethyl ester as a slightly reddish brown oily substance. The obtained target product was purged with nitrogen and stored in a freezer.
¹ H-NMR (CDCl ₃ ) δppm: 1.28 (3H, t, J = 7.1 Hz), 3.81 (3H, s), 4.28 (2H, q, J = 7.1 Hz), 6.87 (2H, d, J = 8.8 Hz), 7.16-7.26 (3H, m), 12.02 (1H, d, J = 12.5 Hz).

  The compounds of Reference Examples 47 to 57 below were produced in the same manner as in Reference Example 46 using appropriate starting materials.

Reference Example 47
2,4-Dimethoxy-α- (hydroxymethylene) phenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.21 (3H, t, J = 7.1 Hz), 3.76 (3H, s), 3.81 (3H, s), 4.22 (2H, q, J = 7.1 Hz), 6.43− 6.49 (2H, m), 7.00 (1H, d, J = 8.9Hz), 7.12 (1H, d, J = 12.6Hz), 11.89 (1H, d, J = 12.6Hz).

Reference Example 48
2,4-Dichloro-α- (hydroxymethylene) phenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.15 (3H, t, J = 7.2 Hz), 4.22 (2H, q, J = 7.2 Hz), 7.11-7.26 (3H, m), 7.40-7.43 (1H, m ), 12.00 (1H, d, J = 12.2 Hz).

Reference Example 49
α- (Hydroxymethylene) -2-methoxyphenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.19 (3H, t, J = 7.1 Hz), 3.79 (3H, s), 4.21 (2H, q, J = 7.1 Hz), 6.86-7.68 (5H, m), 11.91 (1H, d, J = 12.3 Hz).

Reference Example 50
α- (Hydroxymethylene) -2-isopropoxy-4-methoxyphenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.20-1.31 (9H, m), 3.80 (3H, s), 4.17 (2H, q, J = 7.1 Hz), 4.43-4.47 (1H, m), 6.42-6.46 (2H, m), 6.90-7.12 (2H, m), 11.85 (1H, d, J = 12.6 Hz).

Reference Example 51
α- (Hydroxymethylene) -4-methoxy-2-methylphenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.20 (3H, t, J = 7.2 Hz), 2.19 (3H, s), 3.80 (3H, s), 4.22 (2H, q, J = 7.2 Hz), 6.54− 6.75 (2H, m), 7.02-7.26 (2H, m), 11.94 (1H, d, J = 12.7 Hz).

Reference Example 52
2-Fluoro-α- (hydroxymethylene) -4-methoxyphenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.22 (3H, t, J = 7.1 Hz), 3.80 (3H, s), 4.21 (2H, q, J = 7.1 Hz), 6.61-6.69 (2H, m), 7.03-7.26 (2H, m), 12.05 (1H, d, J = 12.3 Hz).

Reference Example 53
4-Ethoxy-α- (hydroxymethylene) -2-methoxyphenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.19−1.45 (6H, m), 3.75 (3H, s), 4.00−4.26 (4H, m), 6.42−6.48 (2H, m), 6.97−7.26 (2H, m), 11.86 (1H, d, J = 12.3 Hz).

Reference Example 54
α- (Hydroxymethylene) -4-isopropoxy-2-methoxyphenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.20-1.31 (9H, m), 3.75 (3H, s), 4.16 (2H, q, J = 7.2 Hz), 4.43-4.47 (1H, m), 6.43-6.48 (2H, m), 6.99-7.22 (2H, m), 11.87 (1H, d, J = 12.3 Hz).

Reference Example 55
4-Cyclopropylmethoxy-α- (hydroxymethylene) phenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 0.35−0.37 (4H, m), 1.24 (3H, t, J = 7.1 Hz), 3.81−3.83 (2H, m), 4.25 (2H, q, J = 7.1 Hz ), 6.85-6.91 (2H, m), 7.16-7.27 (3H, m), 12.02 (1H, d, J = 12.5 Hz).

Reference Example 56
α- (Hydroxymethylene) -4-methylsulfanylphenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.22 (3H, t, J = 7.1 Hz), 2.47 (3H, s), 4.09 (2H, q, J = 7.1 Hz), 6.85-6.94 (2H, m), 7.16-7.26 (3H, m), 11.99 (1H, d, J = 12.3 Hz).

Reference Example 57
4-Ethoxy-α- (hydroxymethylene) phenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.23-1.47 (6H, m), 4.00-4.32 (4H, m), 6.85-6.88 (2H, m), 7.15-7.27 (3H, m), 12.00 (1H, d, J = 12.5 Hz).

Reference Example 58
4-Methoxy-α-propionylphenylacetic acid ethyl ester To a solution of ethyl propionylacetate 3.8 g (26.3 mmol) and 4-iodoanisole 5.0 g (21.3 mmol) in dimethylsulfoxide (DMSO) solution (40 ml) was added L- 980 mg (8.52 mmol) of proline, 810 mg (4.26 mmol) of copper (I) iodide and 27.7 g (85.2 mmol) of cesium carbonate are added in this order, and the mixture is added under nitrogen atmosphere to 40-45. Stir at 27 ° C. for 27 hours. The reaction solution was cooled to room temperature, water and an aqueous ammonium chloride solution were added, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed twice with saturated brine and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 19: 1 → 8: 1). The purified product was concentrated under reduced pressure to obtain 2.97 g (yield 56%) of 4-methoxy-α-propionylphenylacetic acid ethyl ester as a yellow oil.
¹ H-NMR (CDCl ₃ ) δppm: 1.01-1.11 (3H, m), 1.18-1.31 (3H, m), 2.52−2.61 (2H, m), 3.80 and 3.82 (3H, s), 4.15−4.24 ( 2H, m), 4.65 (0.6H, s), 6.84-7.28 (4H, m), 13.13 (0.4H, s).

  The compound of Reference Example 59 below was produced in the same manner as in Reference Example 58 above using appropriate starting materials.

Reference Example 59
α-Acetyl-4-methoxyphenylacetic acid ethyl ester
¹ H-NMR (CDCl ₃ ) δppm: 1.16-1.29 (3H, m), 1.85 (1.4H, s), 2.17 (1.6H, s), 3.80 and 3.82 (1.4 and 1.6H, s), 4.13-4.25 (2H, m), 4.62 (0.6H, s), 6.85-7.28 (4H, m), 13.09 (0.4H, s).

Reference Example 60
5-[(5-Fluoro-2-propoxyphenylamino) methylene] -2,2-dimethyl- [1,3] dioxane-4,6-dione Meldrum acid 5.29 g (36.7 mmol) The mixture was added to 31 ml of methyl, and the mixture was stirred for 2 hours with heating under reflux. The resulting mixture was cooled to 50 ° C., and 4.28 g (25.3 mmol) of 5-fluoro-2-propoxyaniline and 3 ml of methyl orthoformate were added thereto. The resulting mixture was stirred for 6 hours with heating under reflux. The resulting reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was recrystallized from methanol to give a pale brown powder of 5-[(5-fluoro-2-propoxyphenylamino) methylene] -2,2-dimethyl- [1,3] dioxane-4,6-dione (7.61 g). (93% yield) was obtained.
¹ H-NMR (CDCl ₃ ) δppm: 1.12 (3H, t, J = 7.4Hz), 1.75 (6H, s), 1.85-1.98 (2H, m), 4.02 (2H, t, J = 6.3Hz), 6.86-6.91 (2H, m), 7.06-7.10 (1H, m), 8.60 (1H, d, J = 14.6Hz), 11.68 (1H, d, J = 14.8Hz).

  The compound of Reference Example 61 below was produced in the same manner as in Reference Example 60 above using appropriate starting materials.

Reference Example 61
5-[(2-Cyclopropylmethoxy-5-fluorophenylamino) methylene] -2,2-dimethyl- [1,3] dioxane-4,6-dione
¹ H-NMR (CDCl ₃ ) δppm: 0.39-0.43 (2H, m), 0.65-0.73 (2H, m), 1.31-1.37 (1H, m), 1.75 (6H, s), 3.92 (2H, d, J = 6.9Hz), 6.86-6.91 (2H, m), 7.07-7.11 (1H, m), 8.60 (1H, d, J = 14.5Hz), 11.69 (1H, d, J = 14.3Hz).

Reference Example 62
5-Fluoro-8-propoxy-1H-quinolin-4-one
5-[(5-Fluoro-2-propoxyphenylamino) methylene] -2,2-dimethyl- [1,3] dioxane-4,6-dione (7.6 g, 23.5 mmol) was added to diphenyl ether (15 ml). The mixture was heated with a mantle heater and refluxed for 2 hours. The reaction solution was cooled to room temperature, 5 ml of ethyl acetate and 10 ml of n-hexane were added, the resulting mixture was stirred, and the resulting insoluble material was collected by filtration. The filtrate was recrystallized from a mixed solvent of ethyl acetate / n-hexane to obtain 3.15 g (yield 61%) of 5-fluoro-8-propoxy-1H-quinolin-4-one as a brown powder.
¹ H-NMR (DMSO-d ₆ ) δppm: 1.03 (3H, t, J = 7.3Hz), 1.74-1.88 (2H, m), 4.07 (2H, t, J = 6.4Hz), 5.97 (1H, d , J = 7.4Hz), 6.87 (1H, dd, J = 8.8Hz, 11.9Hz), 7.13 (1H, dd, J = 4.0 Hz, J = 8.8Hz), 7.70 (1H, t, J = 7.2Hz) , 11.07 (1H, brs).

  The compound of Reference Example 63 below was produced in the same manner as in Reference Example 62 using appropriate starting materials.

Reference Example 63
8-Cyclopropylmethoxy-5-fluoro-1H-quinolin-4-one
¹ H-NMR (DMSO-d ₆ ) δppm: 0.34−0.40 (2H, m), 0.55−0.61 (2H, m), 1.27−1.33 (1H, m), 3.98 (2H, d, J = 7.0 Hz) , 5.97 (1H, d, J = 7.4Hz), 6.86 (1H, dd, J = 8.8 Hz, J = 11.9Hz), 7.13 (1H, dd, J = 4.0 Hz, J = 8.8Hz), 7.71 (1H , t, J = 7.4 Hz), 11.10 (1H, brs).

Reference Example 64
5-Fluoro-2-methyl-8-propoxy-1H-quinolin-4-one
To a benzene solution (200 ml) of 10 g (59 mmol) of 5-fluoro-2-propoxyaniline and 7.7 g (59 mmol) of ethyl acetoacetate, 1.0 g of Amberlyst 15 (Sigma Aldrich) was added, and Dean-Stark ( The mixture was stirred with heating at reflux using a Dean-Stark trap. The reaction mixture was cooled to room temperature, filtered to remove the resin, and the filtrate was concentrated under reduced pressure. To the residue was added 20 ml of diphenyl ether, and the mixture was heated with a mantle heater and stirred under reflux for 2 hours. After cooling the reaction solution to room temperature, n-hexane-ethyl acetate (2: 1) was added and the insoluble matter produced was collected by filtration. The residue was washed with n-hexane-ethyl acetate (2: 1) and dried to give 6.0 g of 5-fluoro-2-methyl-8-propoxy-1H-quinolin-4-one as a pale yellow powder (43% yield). %).
¹ H-NMR (DMSO-d ₆ ) δppm: 0.97 (3H, t, J = 7.3 Hz), 1.77−1.87 (2H, m), 2.34 (3H, s), 4.08 (2H, t, J = 6.4 Hz) ), 5.84 (1H, s), 6.79-6.88 (1H, m), 7.10-7.14 (1H, m), 10.58 (1H, brs).

Reference Example 65
5-Fluoro-3-iodo-8-propoxy-1H-quinolin-4-one
1.0 g (4.52 mmol) of 5-fluoro-8-propoxy-1H-quinolin-4-one was suspended in 11 ml of DMF, and 0.7 g (5.06 mmol) of potassium carbonate and 1.27 g of iodine were suspended in the suspension. (5.00 mmol) was added and the resulting mixture was stirred at room temperature for 3 hours. The reaction solution was poured into an aqueous solution (45 ml) of 3.94 g (25 mmol) of sodium thiosulfate and the mixture was stirred for 5 minutes. Ethyl acetate was added to the resulting reaction mixture and stirred, and the insoluble material was collected by filtration. The filtrate was separated, and the organic layer was washed with saturated brine and concentrated under reduced pressure. The residue and the insoluble matter collected by filtration were combined and purified by silica gel column chromatography (dichloromethane: methanol = 50: 1 → 40: 1). The purified product was concentrated to dryness under reduced pressure to obtain 1.25 g (yield 80%) of 5-fluoro-3-iodo-8-propoxy-1H-quinolin-4-one as a light brown powder.
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.4Hz), 1.78-1.86 (2H, m), 4.09 (2H, t, J = 6.5Hz), 6.97 (1H, dd , J = 8.8 Hz, J = 11.9 Hz), 7.19 (1H, dd, J = 4.0 Hz, J = 8.8 Hz), 8.19 (1H, s), 11.44 (1H, brs).

  The compounds of Reference Examples 66 and 67 below were produced in the same manner as in Reference Example 65 using appropriate starting materials.

Reference Example 66
5-Fluoro-3-iodo-2-methyl-8-propoxy-1H-quinolin-4-one
¹ H-NMR (CDCl ₃ ) δppm: 0.97 (3H, t, J = 7.4 Hz), 1.78−1.88 (2H, m), 2.70 (3H, s), 6.92−7.00 (1H, m), 7.17−7.22 (1H, m).

Reference Example 67
8-cyclopropylmethoxy-5-fluoro-3-iodo-1H-quinolin-4-one
¹ H-NMR (DMSO-d ₆ ) δppm: 0.36−0.40 (2H, m), 0.56−0.63 (2H, m), 1.28−1.31 (1H, m), 3.99 (2H, d, J = 7.0 Hz) 6.97 (1H, dd, J = 8.8 Hz, J = 11.9 Hz), 7.19 (1H, dd, J = 4.0 Hz, J = 8.8 Hz), 8.19 (1H, s), 11.48 (1H, brs).

Reference Example 68
8-cyclopropylmethoxy-1-ethyl-5-fluoro-3-iodo-1H-quinolin-4-one
To a solution of 910 mg (2.53 mmol) of 8-cyclopropylmethoxy-5-fluoro-3-iodo-1H-quinolin-4-one in DMF (5 ml) was added 450 mg (3.26 mmol) of potassium carbonate and Stir for minutes at room temperature. To this was added 0.31 ml (3.87 mmol) of ethyl iodide and the mixture was stirred at 60 ° C. for 2 hours. The reaction was cooled to room temperature, water was added, and the resulting mixture was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane: ethyl acetate = 40: 1 → 15: 1). The purified product was concentrated to dryness under reduced pressure to obtain 750 mg (77% yield) of 8-cyclopropylmethoxy-1-ethyl-5-fluoro-3-iodo-1H-quinolin-4-one as a light brown powder. It was.
¹ H-NMR (DMSO-d ₆ ) δppm: 0.34−0.38 (2H, m), 0.57−0.64 (2H, m), 1.26−1.36 (4H, m), 3.93 (2H, d, J = 7.3 Hz) , 4.56 (2H, q, J = 7.0Hz), 7.05 (1H, dd, J = 8.9 Hz, J = 11.4Hz), 7.24 (1H, dd, J = 4.6 Hz, J = 9.0Hz), 8.45 (1H , s).

Reference Example 69
2,2,2-trifluoro-N- (5-fluoro-2-propoxyphenyl) acetamide
A dichloromethane solution (60 ml) of 10.0 g (59.1 mmol) of 5-fluoro-2-propoxyaniline was ice-cooled, and 16.5 ml of triethylamine was added thereto, and then 14.8 g (70.5 g) of trifluoroacetic anhydride was added. Mmol) and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction solution, and the resulting mixture was extracted with dichloromethane. The organic layer was washed with water and dried over anhydrous sodium sulfate. The obtained dried product was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 10: 1). The purified product was concentrated to dryness under reduced pressure to obtain 15.83 g (yield 99%) of 2,2,2-trifluoro-N- (5-fluoro-2-propoxyphenyl) acetamide as a white powder.
¹ H-NMR (CDCl ₃ ) δppm: 1.03 (3H, t, J = 7.5 Hz), 1.79-1.93 (2H, m), 3.98 (2H, t, J = 6.5 Hz), 6.80-6.86 (2H, m ), 8.10-8.12 (1H, m), 8.64 (1H, brs).

Reference Example 70
4,4,4-trifluoro-3- (5-fluoro-2-propoxyphenylamino) but-2-enoic acid ethyl ester 2,2,2-trifluoro-N- (5-fluoro-2-propoxyphenyl) ) 41.52 g (119.2 mmol) of carboethoxymethylenetriphenylphosphorane was added to a toluene solution (100 ml) of 15.83 g (59.1 mmol) of acetamide, and the mixture was stirred for 4 hours under heating and reflux in a nitrogen atmosphere. . The stirred reaction mixture was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 10: 1). The purified product was concentrated under reduced pressure to give 19.7 g (yield 99) of 4,4,4-trifluoro-3- (5-fluoro-2-propoxyphenylamino) but-2-enoic acid ethyl ester as a yellow oil. %).
¹ H-NMR (CDCl ₃ ) δppm: 1.02 (3H, t, J = 7.5 Hz), 1.28 (3H, t, 7.0 Hz), 1.74−1.88 (2H, m), 3.85 (2H, t, J = 6.5 Hz), 4.17 (2H, q, J = 7.0 Hz), 5.41 (1H, s), 6.77-6.97 (3H, m), 9.77 (1H, brs).

Reference Example 71
5-Fluoro-8-propoxy-2-trifluoromethyl-1H-quinolin-4-one 4,4,4-trifluoro-3- (5-fluoro-2-propoxyphenylamino) but-2-enoic acid ethyl To 19.7 g (59.0 mmol) of the ester, 15 ml of diphenyl ether was added, and the mixture was stirred for 1.5 hours under heating to reflux. The reaction solution was cooled to room temperature, n-hexane was added, and the deposited precipitate was collected by filtration. The residue was washed with n-hexane and dried to obtain 16.2 g (yield 94%) of white powder of 5-fluoro-8-propoxy-2-trifluoromethyl-1H-quinolin-4-one.
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00 (3H, t, J = 7.5 Hz), 1.76-1.90 (2H, m), 4.07 (2H, t, J = 6.5 Hz), 7.18-7.32 (3H m), 12.26 (1H, brs).

Reference Example 72
5-fluoro-3-iodo-8-propoxy-2-trifluoromethyl-1H-quinolin-4-one 5-fluoro-8-propoxy-2-trifluoromethyl-1H-quinolin-4-one 6.0 g ( 20.7 mmol) in DMF (20 ml) were added in succession with potassium carbonate 3.73 g (27 mmol) and iodine 6.85 g (27 mmol), and the mixture was stirred at room temperature for 1.5 hours. 20 ml of saturated aqueous sodium sulfite solution and ethyl acetate were added to the reaction solution, and the precipitated solid was collected by filtration. The filtrate was washed with water and dried over anhydrous sodium sulfate. The dried filtrate was concentrated under reduced pressure, the residue and the filtrate collected earlier were combined, dissolved in ethanol, and concentrated. The residue was recrystallized from a mixed solvent of ethyl acetate-n-hexane to give 4.7 g (yield) of white powder of 5-fluoro-3-iodo-8-propoxy-2-trifluoromethyl-1H-quinolin-4-one. Rate 55%).
¹ H-NMR (DMSO-d ₆ ) δppm: 0.96 (3H, t, J = 7.5 Hz), 1.70−1.80 (2H, m), 3.95 (2H, t, J = 6.5 Hz), 6.64−6.85 (2H m), 12.02 (1H, brs).

Reference Example 73
1- (5-Bromo-2-cyclopentyloxyphenyl) ethanone 6.5 ′ g (47.4 mmol) of potassium carbonate in a DMF solution (10 ml) of 8.5 g (39.5 mmol) of 5′-bromo-2′-hydroxyacetophenone ), 8.25 g (55.3 mmol) of cyclopentyl bromide and 5 ml of DMF were added and stirred at 60 ° C. for 4.5 hours. To this mixture were added 3.0 g (21.7 mmol) of potassium carbonate and 2.0 g (13.4 mmol) of cyclopentyl bromide, and the mixture was stirred at 60 ° C. for 9 hours. The reaction solution was cooled to room temperature, water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 9: 1). The purified product was concentrated under reduced pressure to obtain 11.3 g (yield 100%) of 1- (5-bromo-2-cyclopentyloxyphenyl) ethanone as a pale yellow oil.
¹ H-NMR (CDCl ₃ ) δppm: 1.68-1.95 (8H, m), 2.58 (3H, s), 4.83-4.87 (1H, m), 6.83 (1H, d, J = 8.9Hz), 7.49 (1H , dd, J = 2.6Hz, 8.9Hz), 7.82 (1H, d, J = 2.6Hz).

Reference Example 74
1- (5-Bromo-2-cyclopentyloxyphenyl) ethanone oxime 1- (5-Bromo-2-cyclopentyloxyphenyl) ethanone 5.0 g (17.65 mmol) was dissolved in a mixed solvent of 18 ml chloroform and 70 ml methanol. did. To the resulting solution were added 1.88 g (27.0 mmol) of hydroxylamine hydrochloride and 4.36 ml (54.1 mmol) of pyridine, and the mixture was stirred with heating under reflux for 6 hours. The reaction solution was cooled to room temperature and then concentrated under reduced pressure. To the residue was added 13.9 ml of 2N hydrochloric acid, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over magnesium sulfate, and concentrated to dryness under reduced pressure. The residue was washed with n-hexane and dried to obtain 4.6 g (yield 87%) of 1- (5-bromo-2-cyclopentyloxyphenyl) ethanone oxime as a white powder.
¹ H-NMR (CDCl ₃ ) δppm: 1.65-1.90 (8H, m), 2.17 (3H, s), 4.72-4.76 (1H, m), 6.76 (1H, d, J = 8.4Hz), 7.35-7.41 (2H, m), 7.99 (1H, brs).

Reference Example 75
N- (5-bromo-2-cyclopentyloxyphenyl) acetamide 4.56 g (15.3 mmol) of 1- (5-bromo-2-cyclopentyloxyphenyl) ethanone oxime was suspended in 100 ml of acetonitrile, and indium chloride was suspended therein. (III) 507 mg (2.29 mmol) was added, and the mixture was heated to reflux for 2 hours under a nitrogen atmosphere. The reaction solution was cooled to room temperature and then concentrated under reduced pressure. The residue was extracted with dichloromethane. The organic layer was washed with saturated brine and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 8: 1 → 4: 1). The purified product was concentrated under reduced pressure to obtain 3.41 g (yield 75%) of N- (5-bromo-2-cyclopentyloxyphenyl) acetamide as a pale yellow oil.
¹ H-NMR (CDCl ₃ ) δppm: 1.67-1.94 (8H, m), 2.18 (3H, s), 4.75-4.81 (1H, m), 6.72 (1H, d, J = 8.7Hz), 7.10 (1H , dd, J = 2.3Hz, 8.7Hz), 7.67 (1H, brs), 8.55 (1H, d, J = 2.3Hz).

Reference Example 76
5-Bromo-2-cyclopentyloxyaniline N- (5-Bromo-2-cyclopentyloxyphenyl) acetamide 3.4 g (11.4 mmol) in ethanol solution (100 ml) was added concentrated hydrochloric acid 5.8 ml and heated under reflux. For 3 hours. After the reaction solution was cooled to room temperature, 14.2 ml of 5N sodium hydroxide aqueous solution was added thereto to adjust to pH = 11 and extracted with dichloromethane. The organic layer was washed with saturated brine and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 4: 1). The purified product was concentrated under reduced pressure to obtain 2.97 g (yield: 100%) of 5-bromo-2-cyclopentyloxyaniline as a pale yellow oil.
¹ H-NMR (CDCl ₃ ) δppm: 1.62-1.89 (8H, m), 3.80 (2H, brs), 4.71-4.75 (1H, m), 6.61 (1H, d, J = 8.4Hz), 6.75-6.81 (2H, m).

Example 1
5-Fluoro-3-furan-3-yl-8-propoxy-1H-quinolin-4-one
780 mg (2.24 mmol) of 5-fluoro-3-iodo-8-propoxy-1H-quinolin-4-one was suspended in a mixed solvent of 10 ml of toluene and 1.6 ml of methanol, and 752 mg of furan-3-boronic acid. Then, 130 mg (0.11 mmol) of tetrakistriphenylphosphine palladium and 2.25 ml of 2N-sodium carbonate aqueous solution were sequentially added, and the mixture was stirred at 110 ° C. for 20 hours under a nitrogen atmosphere. The reaction was cooled to room temperature, water was added and the resulting mixture was extracted with dichloromethane. The organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane: methanol = 60: 1 → 50: 1). The purified product was concentrated under reduced pressure and recrystallized from ethanol to obtain 180 mg (yield 58%) of 5-fluoro-3-furan-3-yl-8-propoxy-1H-quinolin-4-one as a pale yellow powder. Obtained.
Melting point 214-215 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, J = 7.3Hz), 1.78−1.87 (2H, m), 4.09 (2H, t, J = 6.4Hz), 6.87−6.95 (2H, m ), 7.13 (1H, dd, J = 3.8 Hz, J = 8.8 Hz), 7.67 (1H, s), 8.11 (1H, s), 8.51 (1H, s), 11.50 (1H, brs).

  The compounds of Examples 2 to 5 below were produced in the same manner as in Example 1 using appropriate starting materials.

Example 2
5-Fluoro-3- (3-fluoro-4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one gray powder (ethanol)
Melting point 194-195 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.03 (3H, t, J = 7.3Hz), 1.79-1.87 (2H, m), 3.84 (3H, s), 4.09 (2H, t, J = 6.4Hz ), 6.90 (1H, dd, J = 8.7 Hz, J = 12.1 Hz), 7.12-7.19 (2H, m), 7.35-7.39 (1H, m), 7.56 (1H, dd, J = 2.0 Hz, J = 13.5Hz), 7.87 (1H, s), 11.40 (1H, brs).

Example 3
5-Fluoro-8-propoxy-3-thiophen-3-yl-1H-quinolin-4-one light brown powder (ethanol)
Melting point 208-210 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.4Hz), 1.75-1.89 (2H, m), 4.08 (2H, t, J = 6.4Hz), 6.90 (1H, dd , J = 8.7 Hz, J = 12.1 Hz), 7.13 (1H, dd, J = 3.9 Hz, J = 8.8 Hz), 7.50−7.57 (2H, m), 8.14 (1H, s), 8.19−8.21 (1H , m), 11.42 (1H, brs).

Example 4
3- (3-Chloro-4-methoxyphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one pale yellow powder (ethanol)
Melting point 217-218 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.3Hz), 1.78−1.86 (2H, m), 3.85 (3H, s), 4.08 (2H, t, J = 6.4Hz ), 6.90 (1H, dd, J = 8.8 Hz, J = 12.0Hz), 7.10-7.15 (2H, m), 7.51 (1H, dd, J = 2.1 Hz, J = 8.5Hz), 7.74 (1H, d , J = 2.1 Hz), 7.87 (1H, s), 11.45 (1H, brs).

Example 5
5-Fluoro-8-propoxy-3- (4-trifluoromethoxyphenyl) -1H-quinolin-4-one light gray powder (ethanol)
Melting point 212-214 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.03 (3H, t, J = 7.3 Hz), 1.79-1.87 (2H, m), 4.09 (2H, t, J = 6.4 Hz), 6.92 (1H, dd , J = 8.8 Hz, J = 12.0 Hz), 7.16 (1H, dd, J = 3.9 Hz, J = 8.8 Hz), 7.35 (2H, d, J = 8.5 Hz), 7.73 (2H, d, J = 8.7 Hz), 7.91 (1H, s), 11.45 (1H, brs).

Example 6
5-Fluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one
To a benzene solution (150 ml) of 16.25 g (96.0 mmol) of 5-fluoro-2-propoxyaniline and 21.34 g (96.0 mmol) of α- (hydroxymethylene) -4-methoxyphenylacetic acid ethyl ester was added 1 0.0 g of Amberlyst 15 (Sigma Aldrich) was added and the mixture was stirred with heating at reflux using a Dean-Stark trap for 14 hours. The reaction mixture was cooled to room temperature, filtered to remove the resin, and the filtrate was concentrated under reduced pressure. To the residue was added 40 ml of diphenyl ether, and the mixture was heated with a mantle heater and stirred under reflux for 2 hours. The reaction solution was cooled to room temperature and purified directly by silica gel column chromatography (dichloromethane: methanol = 100: 0 → 30: 1 → 20: 1). The purified product was concentrated under reduced pressure, and the residue was recrystallized from ethanol to give 5.28 g (yield of pale yellow powder of 5-fluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one. 17%) was obtained.
Melting point 196-197 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.3Hz), 1.78−1.86 (2H, m), 3.75 (3H, s), 4.07 (2H, t, J = 6.4Hz ), 6.83-6.96 (3H, m), 7.11 (1H, dd, J = 3.9 Hz, J = 8.8Hz), 7.53 (2H, d, J = 8.8Hz), 7.81 (1H, s), 11.50 (1H , brs).

  The compounds of Examples 7 to 46 below were produced in the same manner as in Example 6 using appropriate starting materials.

Example 7
5-Fluoro-3- (2-methoxyphenyl) -8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 193-195 ° C
¹ H-NMR (CDCl ₃ ) δppm: 1.05 (3H, t, J = 7.5 Hz), 1.82-1.97 (2H, m), 3.77 (3 H, s), 4.05 (2H, t, J = 6.3 Hz) 6.77-7.02 (4H, m), 7.26-7.29 (1H, m), 7.42-7.45 (1H, m), 7.72-7.74 (1H, m), 8.83 (1H, brs).

Example 8
3- (2,4-Dimethoxyphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 116-118 ° C
¹ H-NMR (CDCl ₃ ) δppm: 1.07 (3H, t, J = 7.5 Hz), 1.84−1.98 (2H, m), 3.76 (3H, s), 3.84 (3H, s), 4.06 (2H, t , J = 7.5 Hz), 6.54−6.58 (2H, m), 6.77−6.92 (2H, m), 7.38−7.42 (1H, m), 7.72−7.75 (1H, m), 8.79 (1H, brs).

Example 9
5-Fluoro-8-isopropoxy-3- (4-methoxyphenyl) -1H-quinolin-4-one white powder (ethyl acetate)
Melting point 193-194 ° C
¹ H-NMR (CDCl ₃ ) δ ppm: 1.39 (6H, d, J = 5.0 Hz), 3.79 (3H, s), 4.58 (1H, q, J = 5.0 Hz), 6.79-6.92 (4H, m), 7.54-7.57 (2H, m), 7.68-7.71 (1H, m), 8.80 (1H, brs).

Example 10
3- (2,4-Dichlorophenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 256-259 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.01 (3H, t, J = 7.5 Hz), 1.79-1.87 (2H, m), 4.08 (2H, t, J = 6.3 Hz), 6.88-6.98 (1H m), 6.96-7.72 (1H, m), 7.37-7.47 (2H, m), 7.65-7.67 (1H, m), 7.75-7.77 (1H, m), 11.42 (1H, brs).

Example 11
8-Ethoxy-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 155-156 ° C
¹ H-NMR (CDCl ₃ ) δppm: 1.46 (3H, t, J = 7.5Hz), 3.81 (3H, s), 4.14 (2H, q, J = 7.5 Hz), 6.77-6.94 (4H, m), 7.54-7.60 (2H, m), 7.71-7.73 (1H, m), 9.02 (1H, brs).

Example 12
3- (2,4-Dimethoxyphenyl) -8-ethoxy-5-fluoro-1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 154-155 ° C
¹ H-NMR (CDCl ₃ ) δppm: 1.44 (3H, t, J = 7.5 Hz), 3.73 (3H, s), 3.81 (3H, s), 4.12 (2H, q, J = 7.5 Hz), 6.50− 6.53 (2H, m), 6.54-6.89 (2H, m), 7.35-7.39 (1H, m), 7.69-7.72 (1H, m), 8.97 (1H, brs).

Example 13
3- (2,4-Dichlorophenyl) -8-ethoxy-5-fluoro-1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 236-237 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.40 (3H, t, J = 7.5 Hz), 4.17 (2H, q, J = 7.5 Hz), 6.88−7.00 (1H, m), 7.22−7.32 (1H m), 7.38-7.45 (2H, m), 7.64-7.65 (1H, m), 7.74-7.75 (1H, m), 11.40 (1H, brs).

Example 14
5-Fluoro-3- (4-methoxyphenyl) -8-morpholin-4-yl-1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 249-251 ° C
¹ H-NMR (CDCl ₃ ) δppm: 2.75−3.22 (4H, m), 3.65−4.15 (4H, m), 6.85−6.93 (3H, m), 7.34−7.40 (1H, m), 7.54−7.58 ( 2H, m), 7.74-7.77 (1H, m), 10.02 (1H, brs).
Example 15
5-Fluoro-3- (2-isopropoxy-4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 204-206 ° C
¹ H-NMR (CDCl ₃ ) δppm: 1.09 (3H, t, J = 6.3 Hz), 1.23 (3H, s), 1.26 (3H, s), 1.87−2.01 (2H, m), 3.83 (3H, s ), 4.08 (2H, t, J = 6.3 Hz), 4,34−4.50 (1H, m), 6.55−6.60 (2H, m), 6.78−6.93 (2H, m), 7.50 (1H, d, J = 7.5 Hz), 7.80 (1H, d, J = 7.5 Hz), 8.73 (1H, brs).

Example 16
5-Fluoro-3- (4-methoxy-2-methylphenyl) -8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 197-199 ° C
¹ H-NMR (CDCl ₃ ) δppm: 1.06 (3H, t, J = 6.3 Hz), 1.80-2.00 (2H, m), 2.24 (3H, s), 3.80 (3H, s), 4.07 (2H, t , J = 6.3 Hz), 6.70-6.94 (4H, m), 7.07 (1H, d, J = 7.5 Hz), 7.54 (1H, d, J = 7.5 Hz), 8.80 (1H, brs).

Example 17
5-Fluoro-3- (2-fluoro-4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one white powder (ethyl acetate-ethanol)
Melting point 230-232 ℃
¹ H-NMR (CDCl ₃ ) δppm: 1.05 (3H, t, J = 7.5 Hz), 1.80-2.00 (2H, m), 3.80 (3H, s), 4.06 (2H, t, J = 7.5 Hz), 6.64-6.93 (4H, m), 7.53-7.60 (1H, m), 7.74-7.78 (1H, m), 8.86 (1H, brs).

Example 18
5-Fluoro-3- (4-methoxyphenyl) -8-pyrrolidin-1-yl-1H-quinolin-4-one light brown powder (ethyl acetate-n-hexane)
Melting point 100-105 ° C
¹ H-NMR (CDCl ₃ ) δ ppm: 1.90−2.08 (4H, m), 3.01−3.20 (4H, m), 3.81 (3H, s), 6.81−6.94 (3H, m), 7.29−7.34 (1H, m), 7.55-7.60 (2H, m), 7.74-7.76 (1H, m), 9.41 (1H, brs).

Example 19
3- (4-Ethoxy-2-methoxyphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one light brown powder (ethyl acetate)
Melting point 118-120 ° C
¹ H-NMR (CDCl ₃ ) δppm: 1.06 (3H, t, J = 7.5 Hz), 1.39 (3H, t, J = 7.5 Hz), 1.83−1.98 (2H, m), 3.75 (3H, s), 4.00−4.14 (4H, m), 6.51−6.55 (2H, m), 6.76−6.91 (2H, m), 7.38 (1H, d, J = 6.2 Hz), 7.72 (1H, d, J = 6.2 Hz) , 8.65 (1H, brs).

Example 20
5-Fluoro-3- (4-isopropoxy-2-methoxyphenyl) -8-propoxy-1H-quinolin-4-one white powder (ethyl acetate-n-hexane)
Melting point 113-115 ° C
¹ H-NMR (CDCl ₃ ) δppm: 1.04 (3H, t, J = 7.5 Hz), 1.33 (3H, s), 1.36 (3H, s), 1.80-1.95 (2H, m), 3.72 (3H, s ), 4.03 (2H, t, J = 7.5 Hz), 4.50−4.71 (1H, m), 6.49−6.53 (2H, m), 6.78−6.86 (2H, m), 7.34−7.38 (1H, m), 7.42-7.74 (1H, m), 8.82 (1H, brs).

Example 21
5,6-Difluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one pale brown powder (ethyl acetate-n-hexane)
Melting point 198-200 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.3Hz), 1.78−1.86 (2H, m), 3.75 (3H, s), 4.11 (2H, t, J = 6.4Hz ), 6.93 (2H, d, J = 8.8Hz), 7.38 (1H, dd, J = 6.5 Hz, J = 12.3Hz), 7.54 (2H, d, J = 8.8Hz), 7.81 (1H, s), 11.50 (1H, brs).

Example 22
8-Bromo-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 134-135 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 3.78 (3H, s), 6.94−7.02 (3H, m), 7.52 (2H, d, J = 6.3 Hz), 7.84 (1H, s), 7.89−8.00 (1H, m), 11.20 (1H, brs).

Example 23
5-Fluoro-3- (4-methoxyphenyl) -8- (pyrrolidin-1-carbonyl) -1H-quinolin-4-one orange powder (ethyl acetate)
Melting point 236-237 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.77-1.91 (4H, m), 3.29-3.34 (2H, m), 3.54-3.59 (2H, m), 3.76 (3H, s), 6.94 (2H, d, J = 8.7Hz), 7.02 (1H, dd, J = 8.3 Hz, J = 11.8Hz), 7.53 (2H, d, J = 8.7Hz), 7.71 (1H, dd, J = 5.1 Hz, J = 8.3Hz), 7.88 (1H, s), 11.26 (1H, s).

Example 24
8-cyclopropylmethoxy-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one pale yellow powder (ethyl acetate-ethanol)
Melting point 190-191 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.33−0.39 (2H, m), 0.55−0.62 (2H, m), 1.26−1.34 (1H, m), 3.75 (3H, s), 3.99 (2H, d, J = 7.0Hz), 6.83-6.95 (3H, m), 7.12 (1H, dd, J = 3.8 Hz, J = 8.8Hz), 7.53 (2H, d, J = 8.6Hz), 7.82 (1H, s), 11.34 (1H, brs).

Example 25
8- (N-cyclohexyl-N-methylamino) -5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 224-225 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00-1.24 (5H, m), 1.53-1.99 (5H, m), 2.65 (3H, s), 3.78 (3H, s), 6.92-6.99 (3H, m), 7.50-7.57 (3H, s), 7.87 (1H, s), 10.93 (1H, brs).

Example 26
N- {3- [5-Fluoro-3- (4-methoxyphenyl) -4-oxo-1,4-dihydroquinolin-8-yloxy] propyl} acetamide light brown powder (ethanol)
Melting point 229-231 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.80 (3H, s), 1.91-1.96 (2H, m), 3.24-3.31 (2H, m), 3.74 (3H, s), 4.12 (2H, t, J = 5.6 Hz), 6.84−7.13 (4H, m), 7.53 (2H, d, J = 8.6 Hz), 7.83 (1H, s), 8.01 (1H, brs), 11.40 (1H, brs).
N- {3- [5-Fluoro-3- (4-methoxy-phenyl) -4-oxo-1,4-dihydro-quinolin-8-yloxy] -propyl} -methanesulfonamide
Example 27
N- {3- [5-Fluoro-3- (4-methoxyphenyl) -4-oxo-1,4-dihydroquinolin-8-yloxy] propyl} methanesulfonamide light brown powder (ethanol)
Melting point 120-121 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.96-2.06 (2H, m), 2.88 (3H, s), 3.10-3.30 (2H, m), 3.75 (3H, s), 4.18 (2H, t, J = 5.9Hz), 6.85-6.95 (3H, m), 7.00-7.16 (2H, m), 7.54 (2H, d, J = 8.7Hz), 7.82 (1H, s), 11.34 (1H, brs).

Example 28
5-Fluoro-8- (N-isobutyl-N-methylamino) -3- (4-methoxyphenyl) -1H-quinolin-4-one white powder (ethyl acetate)
Melting point 144-145 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.86 (3H, s), 0.91 (3H, s), 1.61-1.67 (1H, m), 2.61 (3H, s), 2.80 (2H, d, J = 6.75 Hz), 3.79 (3H, s), 6.91-6.99 (3H, m), 7.46-7.57 (3H, m), 7.88 (1H, s), 11.02 (1H, brs).

Example 29
5-Fluoro-8- (N-isopropyl-N-methylamino) -3- (4-methoxyphenyl) -1H-quinolin-4-one white powder (ethyl acetate)
Melting point 267-269 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.04 (3H, s), 1.06 (3H, s), 2.62 (3H, s), 3.10-3.18 (1H, m), 3.76 (3H, s), 6.90 -6.98 (3H, m), 7.47-7.55 (3H, m), 7.85 (1H, s), 10.94 (1H, brs).

Example 30
5-Fluoro-3- (4-methoxyphenyl) -8- (N-methyl-N-propylamino) -1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 145-146 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.79 (3H, t, J = 7.5 Hz), 1.31-1.45 (2H, m), 2.63 (3H, s), 2.85 (2H, t, J = 7.5 Hz ), 3.76 (3H, s), 6.89-6.97 (3H, m), 7.43-7.54 (3H, m), 7.82 (1H, s), 11.07 (1H, brs).

Example 31
5-Fluoro-3- (4-methoxyphenyl) -8- (4,4,4-trifluorobutoxy) -1H-quinolin-4-one white powder (ethyl acetate)
Melting point 171-172 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.99−2.08 (2H, m), 2.48−2.61 (2H, m), 3.74 (3H, s), 4.17 (2H, t, J = 5.9 Hz), 6.84 −6.94 (3H, m), 7.11 (1H, dd, J = 3.8 Hz, J = 8.8Hz), 7.53 (2H, d, J = 8.7Hz), 7.82 (1H, s), 11.40 (1H, brs) .

Example 32
1- {3- [5-Fluoro-3- (4-methoxyphenyl) -4-oxo-1,4-dihydroquinolin-8-yloxy] propyl} -1,3,3-trimethylurea brown amorphous solid ( Diethyl ether)
¹ H-NMR (DMSO-d ₆ ) δppm: 2.00−2.05 (2H, m), 2.63 (6H, s), 2.74 (3H, s), 3.20−3.40 (2H, m), 3.76 (3H, s) , 4.12 (2H, t, J = 6.0Hz), 6.85−6.96 (3H, m), 7.14 (1H, dd, J = 3.9 Hz, J = 8.8Hz), 7.55 (2H, d, J = 8.7Hz) , 7.81 (1H, s), 11.40 (1H, brs).

Example 33
3- (4-Ethoxyphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 203-205 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.3 Hz), 1.13 (3H, t, J = 7.0 Hz), 1.76−1.91 (2H, m), 3.99−4.13 (4H m), 6.84-6.94 (3H, m), 7.12-7.17 (1H, m), 7.50 (2H, d, J = 7.5 Hz), 7.79 (1H, s), 11.25 (1H, brs).

Example 34
5-Fluoro-8- [N- (2-methoxyethyl) -N-methylamino] -3- (4-methoxyphenyl) -1H-quinolin-4-one hydrochloride light yellow powder (ethyl acetate)
Melting point 100-101 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 2.78 (3H, s), 3.08 (2H, t, J = 5.3 Hz), 3.33 (3H, s), 3.49 (2H, t, J = 5.3 Hz), 3.81 (3H, s), 6.94−7.02 (3H, m), 7.50−7.62 (3H, m), 8.00 (1H, s), 11.16 (1H, brs).

Example 35
3- (4-Cyclopropylmethoxyphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 162-163 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.30-0.35 (2H, m), 0.54-0.58 (2H, m), 1.01 (3H, t, J = 7.5 Hz), 1.10-1.30 (1H, m) , 1.72-1.91 (2H, m), 3.80 (2H, d, J = 7.0 Hz), 4.07 (2H, t, J = 6.4 Hz), 6.84−6.93 (3H, m), 7.11−7.16 (1H, m ), 7.50 (2H, d, J = 8.8 Hz), 7.79 (1H, s), 11.25 (1H, brs).

Example 36
5-Fluoro-8- (2-methoxyethoxy) -3- (4-methoxyphenyl) -1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 142-144 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 3.31 (3H, s), 3.70-3.80 (2H, m), 3.75 (3H, s), 4.20-4.30 (2H, m), 6.84-6.94 (3H, m), 7.16 (1H, dd, J = 3.6 Hz, J = 8.7 Hz), 7.53 (2H, d, J = 8.4 Hz), 7.82 (1H, s), 11.10 (1H, brs).

Example 37
8-cyclopentyloxy-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 213-215 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.50-1.70 (2H, m), 1.71-2.00 (6H, m), 3.75 (3H, s), 4.92-4.95 (1H, m), 6.83-6.95 ( 3H, m), 7.09 (1H, dd, J = 3.9 Hz, J = 8.8 Hz), 7.53 (2H, d, J = 8.6 Hz), 7.80 (1H, s), 11.20 (1H, brs).

Example 38
5-Fluoro-3- (4-methylsulfanylphenyl) -8-propoxy-1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 198-199 ° C
¹ H-NMR (CDCl ₃ ) δppm: 1.07 (3H, t, J = 7.4 Hz), 1.85−2.04 (2H, m), 2.50 (3H, s), 4.07 (2H, t, J = 6.6 Hz), 6.80-6.94 (2H, m), 7.27-7.31 (2H, m), 7.56 (2H, d, J = 8.4 Hz), 7.74 (1H, d, J = 8.2 Hz), 8.81 (1H, brs).

Example 39
5-Fluoro-3- (4-methoxyphenyl) -8- (tetrahydrofuran-2-ylmethoxy) -1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 108-110 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.67−1.75 (1H, m), 1.81-1−1.90 (2H, m), 2.02−2.09 (1H, m), 3.65−3.83 (2H, m), 3.75 ( 3H, s), 4.10 (2H, d, J = 4.6Hz), 4.25−4.29 (1H, m), 6.84−6.95 (3H, m), 7.17 (1H, dd, J = 3.8 Hz, J = 8.8Hz ), 7.53 (2H, d, J = 8.7Hz), 7.82 (1H, s), 11.20 (1H, brs).

Example 40
5-Fluoro-3- (4-methoxyphenyl) -8-propylsulfanyl-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 173-174 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.90 (3H, t, J = 7.3 Hz), 1.40−1.52 (2H, m), 2.79 (2H, t, J = 7.2 Hz), 3.77 (3H, s ), 6.93−7.04 (3H, m), 7.51−7.55 (2H, m), 7.79−7.87 (2H, m), 11.24 (1H, brs).

Example 41
8-cyclobutylmethoxy-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 193-194 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.79-1.93 (4H, m), 2.04−2.09 (2H, m), 2.76−2.81 (1H, m), 3.74 (3H, s), 4.08 (2H, d, J = 6.8Hz), 6.83−6.93 (3H, m), 7.11 (1H, dd, J = 3.8 Hz, J = 8.8Hz), 7.52 (2H, d, J = 8.6Hz), 7.82 (1H, s), 11.20 (1H, brs).

Example 42
8-tert-butoxy-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one light brown powder (ethyl acetate-diethyl ether)
Melting point 206-208 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.40 (9H, s), 3.76 (3H, s), 6.84-6.96 (3H, m), 7.31 (1H, dd, J = 4.3 Hz, J = 8.8 Hz ), 7.54 (2H, d, J = 8.8Hz), 7.82 (1H, s), 10.95 (1H, brs).

Example 43
5-Fluoro-8-methoxy-3- (4-methoxyphenyl) -1H-quinolin-4-one light brown powder (ethyl acetate)
¹ H-NMR (DMSO-d ₆ ) δppm: 3.76 (3H, s), 3.95 (3H, s), 6.87-6.95 (3H, m), 7.15 (1H, dd, J = 3.8 Hz, J = 8.8 Hz ), 7.54 (2H, d, J = 8.7Hz), 7.76 (1H, s), 11.50 (1H, brs).

Example 44
5-Fluoro-8-methoxymethoxy-3- (4-methoxyphenyl) -1H-quinolin-4-one pale brown powder (dichloromethane-methanol)
¹ H-NMR (CDCl ₃ ) δppm: 3.44 (3H, s), 3.76 (3H, s), 5.20 (2H, s), 6.76-6.87 (3H, m), 7.18-7.23 (1H, m), 7.52 (2H, d, J = 7.8Hz), 7.69 (1H, s), 9.68 (1H, brs).

Example 45
8- (3-Benzyloxypropoxy) -5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one brown amorphous solid
¹ H-NMR (DMSO-d ₆ ) δppm: 2.08−2.13 (2H, m), 3.68 (2H, t, J = 6.2Hz), 3.77 (3H, s), 4.22 (2H, t, J = 6.0Hz ), 4.48 (2H, s), 6.84−6.97 (3H, m), 7.13−7.18 (1H, m), 7.21−7.29 (5H, m), 7.55 (2H, d, J = 8.7Hz), 7.76 ( 1H, s), 11.25 (1H, brs).

Example 46
8- (2-Benzyloxypropoxy) -5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one brown amorphous solid
¹ H-NMR (DMSO-d ₆ ) δppm: 1.32 (3H, d, J = 6.2Hz), 3.76 (3H, s), 3.98−4.24 (3H, m), 4.54−4.69 (2H, m), 6.84 -6.96 (3H, m), 7.16-7.30 (6H, m), 7.54 (2H, d, J = 8.7Hz), 7.78 (1H, s), 11.19 (1H, brs).

Example 47
8-Cyclopropylmethoxy-5-fluoro-3- (4-methoxyphenyl) -2-methyl-1H-quinolin-4-one
350 mg of Amberlyst 15 in benzene solution (40 ml) of 760 mg (4.2 mmol) of 2-cyclopropylmethoxy-5-fluoroaniline and 1.0 g (4.2 mmol) of α-acetyl-4-methoxyphenylacetic acid ethyl ester (Sigma-Aldrich) was added and the mixture was stirred with heating at reflux for 19 hours using a Dean-Stark trap. The reaction mixture was cooled to room temperature, filtered to remove the resin, and the filtrate was concentrated under reduced pressure. To the residue was added 2.2 ml of diphenyl ether, and the mixture was heated with a mantle heater and stirred under reflux for 1 hour. The reaction solution was cooled to room temperature and purified directly by silica gel column chromatography (dichloromethane: methanol = 80: 1 → 60: 1). The purified product was concentrated under reduced pressure, and the residue was recrystallized from ethyl acetate to give 8-cyclopropylmethoxy-5-fluoro-3- (4-methoxyphenyl) -2-methyl-1H-quinoline-4 as a pale yellow powder. -Obtained 120 mg (8% yield) of ON.
Melting point 167-169 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.35−0.39 (2H, m), 0.54−0.61 (2H, m), 1.31-1.37 (1H, m), 2.23 (3H, s), 3.76 (3H, s), 4.02 (2H, d, J = 7.0Hz), 6.80-6.94 (3H, m), 7.08-7.18 (3H, m), 10.62 (1H, brs).

  The compound of Example 48 below was produced in the same manner as in Example 47 using appropriate starting materials.

Example 48
2-Ethyl-5-fluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one light brown powder (ethyl acetate-n-hexane)
Melting point 169-171 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.98-1.05 (6H, m), 1.80-1.89 (2H, m), 2.56 (2H, t, J = 7.5Hz), 3.77 (3H, s), 4.13 (2H, t, J = 6.6Hz), 6.81-6.95 (3H, m), 7.05-7.17 (3H, m), 10.40 (1H, brs).

Example 49
5-Fluoro-8-propoxy-3-pyridin-3-yl-1H-quinolin-4-one
600 mg (1.73 mmol) of 5-fluoro-3-iodo-8-propoxy-1H-quinolin-4-one was suspended in 12 ml of 1,2-dimethoxyethane, and 752 mg of 3-pyridineboronic acid was added to the resulting suspension. 1,1′-bis (diphenylphosphino) ferrocenedichloropalladium (II) -dichloromethane complex (PdCl 2 (DPPF)) 76 mg (0.093 mmol) and 2N-sodium carbonate aqueous solution 2.54 ml were sequentially added, and the mixture was The mixture was stirred at 90 ° C. for 2 hours under a nitrogen atmosphere. The reaction was cooled to room temperature, water was added, and the resulting mixture was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane: methanol = 15: 1). The purified product was concentrated under reduced pressure and recrystallized from ethanol to obtain 185 mg (yield 36%) of 5-fluoro-8-propoxy-3-pyridin-3-yl-1H-quinolin-4-one as a light brown powder. Obtained.
Melting point 234-236 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.01 (3H, t, J = 7.3Hz), 1.77-1.86 (2H, m), 4.08 (2H, t, J = 6.4Hz), 6.93 (1H, dd , J = 8.8 Hz, J = 12.0 Hz), 7.13−7.18 (1H, m), 7.37−7.42 (1H, m), 7.97 (1H, s), 8.01−8.05 (1H, m), 8.44−8.46 ( 1H, m), 8.77 (1H, d, J = 2.1 Hz), 11.55 (1H, brs).

  The compounds of Examples 50 to 66 below were produced in the same manner as in Example 49, using appropriate starting materials.

Example 50
3- (4-Ethoxy-3-fluorophenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one pale yellow powder (ethanol)
Melting point 176-177 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.3Hz), 1.33 (3H, t, J = 6.9Hz), 1.75-1.89 (2H, m), 4.05-4.14 (4H , m), 6.90 (1H, dd, J = 8.7 Hz, J = 12.1 Hz), 7.09−7.16 (2H, m), 7.32−7.36 (1H, m), 7.52−7.58 (1H, m), 7.87 ( 1H, s), 11.45 (1H, s).

Example 51
5-Fluoro-8-propoxy-3-pyridin-4-yl-1H-quinolin-4-one light brown powder (ethanol)
Melting point 259-261 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.3Hz), 1.78−1.86 (2H, m), 4.09 (2H, t, J = 6.4Hz), 6.96 (1H, dd , J = 8.8 Hz, J = 12.0 Hz), 7.19 (1H, dd, J = 3.8 Hz, J = 8.8 Hz), 7.71 (2H, d, J = 6.1 Hz), 8.06 (1H, s), 8.52 ( 2H, d, J = 6.1Hz), 11.50 (1H, brs).

Example 52
5-Fluoro-3- (4-phenoxyphenyl) -8-propoxy-1H-quinolin-4-one light brown powder (ethanol)
Melting point 228-230 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.01 (3H, t, J = 7.3Hz), 1.77-1.85 (2H, m), 4.07 (2H, t, J = 6.2Hz), 6.90 (1H, dd , J = 8.8 Hz, J = 12.1 Hz), 6.97−7.02 (4H, m), 7.10−7.15 (2H, m), 7.34−7.63 (4H, m), 7.88 (1H, s), 11.40 (1H, brs).

Example 53
3- (4-Ethylphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 153-154 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.3Hz), 1.17 (3H, t, J = 7.5Hz), 1.78−1.86 (2H, m), 2.59 (2H, q , J = 7.5Hz), 4.08 (2H, t, J = 6.4Hz), 6.89 (1H, dd, J = 8.8 Hz, J = 12.1Hz), 7.10−7.21 (3H, m), 7.50 (2H, d , J = 8.0Hz), 7.83 (1H, s), 11.40 (1H, brs).

Example 54
3- (4-Acetylphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one pale red powder (ethyl acetate)
Melting point 180-181 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.95 (3H, t, J = 7.5 Hz), 1.71-1.83 (2H, m), 2.51 (3H, m), 4.02 (2H, t, J = 6.6 Hz ), 6.84-6.91 (1H, m), 7.10-7.14 (1H, m), 7.72 (2H, d, J = 8.4 Hz), 7.87-7.90 (3H, m), 11.40 (1H, brs).

Example 55
4- (5-Fluoro-4-oxo-8-propoxy-1,4-dihydroquinolin-3-yl) benzoic acid methyl white powder (ethyl acetate)
Melting point 201-202 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.01 (3H, t, J = 7.3 Hz), 1.77-1.91 (2H, m), 3.86 (3H, s), 4.09 (2H, t, J = 6.5 Hz ), 6.90−6.99 (1H, m), 7.17−7.22 (1H, m), 7.80 (2H, d, J = 8.5 Hz), 7.94−7.98 (3H, m), 11.48 (1H, brs).

Example 56
5-Fluoro-8-propoxy-3- [4- (pyrrolidin-1-carbonyl) phenyl] -1H-quinolin-4-one pale red powder (ethyl acetate)
Melting point 236-237 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.4 Hz), 1.79-1.89 (6H, m), 3.43-3.49 (4H, m), 4.08 (2H, t, J = 6.5 Hz), 6.89−6.97 (1H, m), 7.15−7.20 (1H, m), 7.51 (2H, d, J = 8.6 Hz), 7.67 (2H, d, J = 8.6 Hz), 7.90 (1H, s), 11.40 (1H, brs).

Example 57
4- (5-Fluoro-4-oxo-8-propoxy-1,4-dihydroquinolin-3-yl) -N, N-dimethylbenzamide pale brown powder (ethyl acetate)
Melting point 235-237 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.4 Hz), 1.80−1.89 (2H, m), 2.97 (6H, s), 4.08 (2H, t, J = 6.4 Hz) ), 6.89−6.93 (1H, m), 7.15−7.20 (1H, m), 7.39 (2H, d, J = 8.0 Hz), 7.67 (2H, d, J = 8.0 Hz), 7.90 (1H, s) , 11.41 (1H, brs).

Example 58
5-Fluoro-3-furan-2-yl-8-propoxy-1H-quinolin-4-one light brown powder (ethyl acetate)
Melting point 210-212 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.4 Hz), 1.78−1.90 (2H, m), 4.10 (2H, t, J = 6.6 Hz), 6.54−6.56 (1H m), 6.90-6.99 (1H, m), 7.15-7.21 (2H, m), 7.64-7.65 (1H, m), 8.20 (1H, s), 11.47 (1H, brs).

Example 59
5-Fluoro-8-propoxy-3-thiophen-2-yl-1H-quinolin-4-one pale red powder (ethyl acetate)
Melting point 211-213 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.5 Hz), 1.78−1.90 (2H, m), 4.10 (2H, t, J = 6.5 Hz), 6.92−7.20 (3H m), 7.41-7.59 (2H, m), 8.34 (1H, s), 11.63 (1H, brs).

Example 60
3- (5-Fluoro-4-oxo-8-propoxy-1,4-dihydroquinolin-3-yl) thiophene-2-carbaldehyde white powder (ethyl acetate)
Melting point 190-191 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.01 (3H, t, J = 7.4 Hz), 1.79-1.88 (2H, m), 4.08 (3H, t, J = 6.5 Hz), 6.92−7.00 (1H , m), 7.18−7.23 (1H, m), 7.32 (1H, d, J = 5.0 Hz), 7.98 (1H, s), 8.04−8.06 (1H, m), 9.73 (1H, s), 11.40 ( 1H, brs).

Example 61
3- (4-Dimethylaminophenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 206-207 ° C
¹ H-NMR (DMSO-d ₆ ) δ ppm: 1.01 (3H, t, J = 7.4 Hz), 1.79-1.88 (2H, m), 2.90 (6H, s), 4.07 (2H, t, J = 6.4 Hz) ), 6.71 (2H, d, J = 9.0 Hz), 6.82−6.90 (1H, m), 7.09−7.14 (1H, m), 7,45 (2H, d, J = 9.0 Hz), 7.76 (1H, s), 11.18 (1H, brs).

Example 62
3- (3,4-Dimethoxyphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one pale red powder (ethyl acetate)
Melting point 217-218 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.5 Hz), 1.78−1.88 (2H, m), 3.76 (6H, s), 4.07 (2H, t, J = 6.4 Hz) ), 6.85-6.97 (2H, m), 7.08-7.16 (2H, m), 7.30 (1H, s), 7.82 (1H, s), 11.28 (1H, brs).

Example 63
5-Fluoro-3- (6-methoxypyridin-3-yl) -8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 215-216 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.5 Hz), 1.77−1.91 (2H, m), 3.86 (3H, s), 4.08 (2H, t, J = 6.3 Hz) ), 6.81-6.96 (2H, m), 7.14-7.19 (1H, m), 7.77-7.99 (2H, m), 8.35 (1H, s), 11.39 (1H, brs).

Example 64
3- (2,6-Dimethoxypyridin-3-yl) -5-fluoro-8-propoxy-1H-quinolin-4-one pale red powder (ethyl acetate)
Melting point 198-199 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.01 (3H, t, J = 7.3 Hz), 1.76-1.90 (2H, s), 3.83 (3H, s). 3.89 (3H, s), 4.07 (2H , t, J = 6.3 Hz), 6.39 (1H, d, J = 7.1 Hz), 6.86−6.94 (1H, m), 7.13−7.17 (1H, m), 7.68 (1H, d, J = 7.1 Hz) , 7.81 (1H, s), 11.23 (1H, brs).

Example 65
3- (2,5-Dimethoxyphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one pale red powder (ethyl acetate)
Melting point 156-157 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.03 (3H, t, J = 7.3 Hz), 1.80-1.90 (2H, m), 3.65 (3H, s), 3.71 (3H, s), 4.09 (2H , t, J = 6.3 Hz), 6.87-6.91 (4H, m), 6.94-6.95 (1H, m), 7.73 (1H, s), 11.18 (1H, brs).

Example 66
8-cyclopropylmethoxy-1-ethyl-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one brown powder (ethyl acetate-n-hexane)
Melting point 150-152 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.34−0.38 (2H, m), 0.57−0.64 (2H, m), 1.27−1.39 (4H, m), 3.75 (3H, s), 3.92 (2H, d, J = 7.2Hz), 4.60 (2H, q, J = 6.8Hz), 6.91−6.99 (3H, m), 7.17 (1H, dd, J = 4.5 Hz, J = 8.9Hz), 7.60 (2H, d, J = 8.7Hz), 7.98 (1H, s).

Example 67
5-Fluoro-3- (4-methoxyphenyl) -2-methyl-8-propoxy-1H-quinolin-4-one
5-fluoro-3-iodo-2-methyl-8-propoxy-1H-quinolin-4-one 400 mg (1.11 mmol), 4-methoxyphenylboronic acid 504 mg (3.3 mmol), 1,1 100 mg (0.12 mmol) of '-bis (diphenylphosphino) ferrocenedichloropalladium (II) -dichloromethane complex (PdCl 2 (DPPF)) and 1 ml of 2N aqueous sodium carbonate solution are added to 3 ml of 1,2-dimethoxyethane, and the mixture is Heated at 170 ° C. for 10 minutes (microwave reactor). The reaction was cooled to room temperature and filtered through celite. The filtrate was extracted with dichloromethane and washed with water. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 100: 0 → 40: 1). The purified product was concentrated under reduced pressure, and the residue was recrystallized from ethyl acetate to give white powder of 5-fluoro-3- (4-methoxyphenyl) -2-methyl-8-propoxy-1H-quinolin-4-one 230 mg (Yield 61%) was obtained.
Melting point 211-212 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.98 (3H, t, J = 7.3 Hz), 1.79-1.90 (2H, m), 2.23 (3H, s), 3.76 (3H, s), 4.10 (2H , t, J = 6.5 Hz), 6.93−6.95 (2H, m), 7.07−7.09 (2H, m), 7.72−7.73 (1H, m), 7.83 (1H, s), 10.50 (1H, brs).

  The compounds of Examples 68 to 85 below were produced in the same manner as in Example 67, using appropriate starting materials.

Example 68
5-Fluoro-2-methyl-8-propoxy-3-pyridin-3-yl-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 190-192 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.99 (3H, t, J = 7.5 Hz), 1.77−1.89 (2H, m), 2.27 (3H, s), 4.12 (2H, t, J = 6.7 Hz ), 6.85−6.93 (1H, m), 7.16−7.21 (1H, m), 7.38−7.43 (1H, m), 7.63−7.67 (1H, m). 8.40−8.50 (2H, m), 10.70 (1H) , brs).

Example 69
5-Fluoro-2-methyl-8-propoxy-3-pyridin-4-yl-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 265-266 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.99 (3H, t, J = 7.5 Hz), 1.78-1.92 (2H, m), 2.28 (3H, s), 4.12 (2H, t, J = 6.8 Hz ), 6.86−6.94 (1H, m), 7.17−7.21 (1H, m), 7.25 (2H, d, J = 6.0 Hz), 8.55 (2H, d, J = 6.0 Hz), 10.72 (1H, brs) .

Example 70
5-Fluoro-2-methyl-8-propoxy-3- (4-trifluoromethoxyphenyl) -1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 167-168 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.99 (3H, t, J = 7.3 Hz), 1.78−1.92 (2H, m), 2.25 (3H, s), 4.10 (2H, t, J = 6.6 Hz ), 6.83-6.92 (1H, m), 7.15-7.20 (1H, m), 7.31-7.38 (4H, m), 10.64 (1H, brs).

Example 71
3- (4-Ethylphenyl) -5-fluoro-2-methyl-8-propoxy-1H-quinolin-4-one pale red powder (ethyl acetate)
Melting point 221-222 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.99 (3H, t, J = 7.3 Hz), 1.18 (3H, t, J = 7.5 Hz), 1.80−1.89 (2H, m), 2.23 (3H, s ), 2.58 (2H, q, J = 7.5 Hz), 4.10 (2H, t, J = 6.6 Hz), 6.82−6.89 (1H, m), 7.08−7.22 (5H, m), 10.53 (1H, brs) .

Example 72
5-Fluoro-2-methyl-8-propoxy-3-thiophen-2-yl-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 233-234 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.98 (3H, t, J = 7.3 Hz), 1.77−1.89 (2H, m), 2.46 (3H, s), 4.11 (2H, t, J = 6.8 Hz ), 6.86-7.20 (4H, m), 7.52-7.55 (1H, m), 10.70 (1H, brs).

Example 73
3- (4-Dimethylaminophenyl) -5-fluoro-2-methyl-8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 255-257 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00 (3H, t, J = 7.5 Hz), 1.80-1.90 (2H, m), 2.26 (3H, s), 2.91 (6H, s), 4.11 (2H , t, J = 6.6 Hz), 6.72 (2H, d, J = 8.7 Hz), 6.80−6.89 (1H, m), 7.00 (2H, d, J = 8.7 Hz), 7.11−7.17 (1H, m) , 10.45 (1H, brs).

Example 74
5-Fluoro-3- (4-fluorophenyl) -2-methyl-8-propoxy-1H-quinolin-4-one light brown powder (ethyl acetate)
Melting point 196-197 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00 (3H, t, J = 7.3 Hz), 1.80−1.91 (2H, m), 2.25 (3H, s), 4.12 (2H, t, 6.8 Hz), 6.84-6.92 (1H, m), 7.15-7.29 (5H, m), 10.06 (1H, brs).

Example 75
3- (2,4-Dimethoxyphenyl) -5-fluoro-2-methyl-8-propoxy-1H-quinolin-4-one light brown powder (ethyl acetate)
Melting point 100-101 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.99 (3H, t, J = 7.5 Hz), 1.80−1.86 (2H, m), 2.11 (3H, s), 3.65 (3H, s), 3.78 (3H , s), 4.10 (2H, t, J = 6.8 Hz), 6.51-6.59 (2H, m), 6.80-6.94 (2H, m), 7.11-7.17 (1H, m), 10.47 (1H, brs).

Example 76
5-Fluoro-3-furan-2-yl-2-methyl-8-propoxy-1H-quinolin-4-one light brown powder (ethyl acetate)
Melting point 203-204 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.99 (3H, t, J = 7.5 Hz), 1.78−1.89 (2H, m), 2.47 (3H, s), 4.10 (2H, t, J = 6.8 Hz ), 6.52−6.54 (1H, m), 6.67−6.69 (1H, m), 6.86−6.95 (1H, m), 7.15−7.20 (1H, m), 7.67−7.68 (1H, m), 10.66 (1H , m).

Example 77
5-Fluoro-3- (4-methoxyphenyl) -8-propoxy-2-trifluoromethyl-1H-quinolin-4-one white powder (n-hexane-ethyl acetate)
Melting point 170-171 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00 (3H, t, J = 7.3 Hz), 1.76-1.90 (2H, m), 3.80 (3H, s), 4.11 (2H, t, J = 6.5 Hz ), 6.98 (2H, d, J = 8.7 Hz), 7.15−7.25 (4H, m), 10.11 (1H, brs).

Example 78
5-Fluoro-3-furan-2-yl-8-propoxy-2-trifluoromethyl-1H-quinolin-4-one pale yellow powder (n-hexane-ethyl acetate)
Melting point 134-136 ° C
¹ H-NMR (DMSO-d ₆ ) δ ppm: 0.99 (3H, t, J = 7.5 Hz), 1.76-1.90 (2H, m), 4.11 (2H, t, J = 6.6 Hz), 6.59-6.65 (2H , m), 7.21-7.33 (2H, m), 7.81 (1H, m), 10.08 (1H, brs).

Example 79
3- (4-Dimethylaminophenyl) -5-fluoro-8-propoxy-2-trifluoromethyl-1H-quinolin-4-one pale yellow powder (n-hexane-ethyl acetate)
Melting point 176-177 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00 (3H, t, J = 7.4 Hz), 1.76-1.91 (2H, m), 2.94 (6H, s), 4.11 (2H, t, J = 6.6 Hz ), 6.75 (2H, d, J = 8.8 Hz), 7.03 (2H, d, J = 8.8 Hz), 7.21-7.24 (2H, m), 10.00 (1H, brs).

Example 80
3- (4-Ethylphenyl) -5-fluoro-8-propoxy-2-trifluoromethyl-1H-quinolin-4-one white powder (n-hexane-ethyl acetate)
Melting point 187-188 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00 (3H, t, J = 7.3 Hz), 1.20 (3H, t, J = 7.5 Hz), 1.77−1.91 (2H, m), 2.62−2.71 (2H , q, J = 7.5 Hz), 4.12 (2H, t, J = 6.6 Hz), 7.13-7.29 (6H, m), 10.23 (1H, brs).

Example 81
5-Fluoro-3- (4-fluorophenyl) -8-propoxy-2-trifluoromethyl-1H-quinolin-4-one brown powder (n-hexane-ethyl acetate)
Melting point 154-155 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.3 Hz), 1.81-1.89 (2H, m), 4.13 (2H, t, J = 6.5 Hz), 7.10-7.31 (4H , m), 7.80-7.86 (1H, m), 8.08 (1H, s), 10.24 (1H, brs).

Example 82
5-Fluoro-8-propoxy-3- (4-trifluoromethoxyphenyl) -2-trifluoromethyl-1H-quinolin-4-one pale red powder (n-hexane-ethyl acetate)
Melting point 143-144 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00 (3H, t, J = 7.3 Hz), 1.77−1.91 (2H, m), 4.12 (2H, t, J = 6.6 Hz), 7.19−7.54 (6H , m), 10.44 (1H, brs).

Example 83
5-Fluoro-2-isopropyl-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one white powder (ethyl acetate-n-hexane)
Melting point 195-197 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00 (3H, t, J = 7.3 Hz), 1.16 (6H, d, J = 7.0 Hz), 1.78-1.92 (2H, m), 2.86-2.97 (1H , m), 3.77 (3H, s), 4.13 (2H, t, J = 6.4 Hz), 6.84−7.22 (6H, m), 8.98 (1H, brs).

Example 84
5-Fluoro-3-furan-2-yl-2-isopropyl-8-propoxy-1H-quinolin-4-one white powder (ethyl acetate-n-hexane)
Melting point 113-114 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.99 (3H, t, J = 7.5 Hz), 1.21 (6H, d, J = 7.0 Hz), 1.80−1.89 (2H, m), 3.11−3.16 (1H , m), 4.12 (2H, t, J = 6.4 Hz), 6.48−6.54 (2H, m), 6.90−6.98 (1H, m), 7.20−7.25 (1H, m), 7.69−7.70 (1H, m ), 9.29 (1H, brs).

Example 85
5-Fluoro-8-propoxy-3-thiophen-2-yl-2-trifluoromethyl-1H-quinolin-4-one pale yellow powder (ethyl acetate-n-hexane)
Melting point 149-150 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00 (3H, t, J = 7.4 Hz), 1.76-1.90 (2H, m), 4.11 (2H, t, 6.4 Hz), 7.10-7.30 (4H, m ), 7.72-7.75 (1H, m), 10.52 (1H, brs).

Example 86
5-Fluoro-8-furan-2-yl-3- (4-methoxyphenyl) -1H-quinolin-4-one
8-Bromo-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one 150 mg (0.43 mmol), 2-furanboronic acid 145 mg (1.3 mmol), 1,1′-bis 35 mg (0.04 mmol) of (diphenylphosphino) ferrocenedichloropalladium (II) -dichloromethane complex (PdCl ₂ (DPPF)) and 1 ml of 2N aqueous sodium carbonate solution are added to 3 ml of 1,2-dimethoxyethane, and the mixture is heated to 180 ° C. For 10 minutes (microwave reactor). The reaction mixture was cooled to room temperature, dichloromethane was added, and the mixture was filtered through celite. The filtrate was extracted with dichloromethane and washed with water. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane). The purified product was concentrated under reduced pressure, and the residue was recrystallized from n-hexane-ethyl acetate to give 5-fluoro-8-furan-2-yl-3- (4-methoxyphenyl) -1H-quinoline as a slightly orange powder. 100 mg of -4-one (yield 70%) was obtained.
Melting point 209-211 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 3.79 (3H, s), 6.74-6.77 (1H, m), 6.96-7.00 (3H, m), 7.07-7.15 (1H, m), 7.55-7.59 ( 2H, m), 7.81-7.93 (3H, m), 11.00 (1H, brs).

  The compounds of Examples 87 and 88 below were prepared in the same manner as in Example 86 above using appropriate starting materials.

Example 87
5-Fluoro-3- (4-methoxyphenyl) -8-thiophen-3-yl-1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 183-184 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 3.76 (3H, s), 6.93−7.09 (3H, m), 7.30−7.32 (1H, m), 7.49−7.54 (3H, m), 7.76−7.80 ( 3H, m), 10.64 (1H, brs).

Example 88
8-Benzo [b] thiophen-2-yl-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one pale yellow powder (ethyl acetate)
Melting point 276-277 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 3.76 (3H, s), 6.84-6.92 (3H, m), 7.30-7.40 (2H, m), 7.62-7.66 (2H, m), 7.84-7.99 ( 5H, m), 11.03 (1H, brs).

Example 89
4- (5-Fluoro-4-oxo-8-propoxy-1,4-dihydroquinolin-3-yl) benzoic acid
1. Methyl 4- (5-fluoro-4-oxo-8-propoxy-1,4-dihydroquinolin-3-yl) benzoate (330 mg, 0.93 mmol) was suspended in a mixed solvent of ethanol (3 ml) and THF (3 ml). 2 ml of 24N aqueous lithium hydroxide was added and the mixture was stirred at room temperature for 3 hours. Water was added to the reaction solution, and the resulting mixture was extracted with dichloromethane. The organic layer was washed with water, dried over magnesium sulfate, and concentrated to dryness under reduced pressure to give white powder of 4- (5-fluoro-4-oxo-8-propoxy-1,4-dihydroquinoline-3- Yl) 300 mg (yield 95%) of benzoic acid was obtained.
¹ H-NMR (DMSO-d ₆ ) δppm: 1.01-1.07 (3H, t, J = 7.3 Hz), 1.80-1.91 (2H, m), 4.09-4.14 (2H, t, J = 6.4 Hz), 6.85 -7.24 (3H, m), 7.75-7.78 (2H, m), 7.92-7.95 (2H, m), 11.51 (1H, brs), 12.84 (1H, brs).

Example 90
5-Fluoro-3- [4- (morpholine-4-carbonyl) phenyl] -8-propoxy-1H-quinolin-4-one 4- (5-fluoro-4-oxo-8-propoxy-1,4-dihydro 260 mg (0.76 mmol) of quinolin-3-yl) benzoic acid, 99.5 mg (1.14 mmol) of morpholine, 189 mg (0.99 mmol) of WSC and 151 mg (0.99 mmol) of HOBT are added to 10 ml of DMF and the mixture is stirred at room temperature. For 15 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1). The purified product was concentrated under reduced pressure, and the residue was recrystallized from ethyl acetate to give 5-fluoro-3- [4- (morpholine-4-carbonyl) phenyl] -8-propoxy-1H-quinoline-4- 80 mg (26% yield) of ON was obtained.
Melting point 234-236 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.4 Hz), 1.80−1.89 (2H, m), 3.40−3.60 (8H, m), 4.09 (2H, t, J = 6.5 Hz), 6.89−6.98 (1H, m), 7.16−7.21 (1H, m), 7.41 (2H, d, J = 8.3 Hz), 7.69 (2H, d, J = 8.3 Hz), 7.91 (1H, s), 11.41 (1H, brs).

Example 91
5-Fluoro-3- (4-methoxyphenyl) -1-methyl-8-propoxy-1H-quinolin-4-one
5-Fluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one 400 mg (1.22 mmol) in DMF solution (10 ml) and sodium hydride (60% oily) 76 mg (1. 9 mmol) was added and the mixture was stirred at room temperature for 15 minutes. To this was added 225 mg (1.6 mmol) of methyl iodide and the resulting mixture was stirred at room temperature for 19 hours. Water and ethyl acetate were added to the reaction solution and the phases were separated, and the organic layer was washed with water. After drying over anhydrous sodium sulfate, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 1: 1). The purified product was concentrated under reduced pressure, and the residue was recrystallized from ethyl acetate to give 5-fluoro-3- (4-methoxyphenyl) -1-methyl-8-propoxy-1H-quinolin-4-one as a pale yellow powder. 365 mg (yield 72%) was obtained.
Melting point 147-148 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.98 (3H, t, J = 7.5 Hz), 1.77 (2H, m), 3.76 (3H, s), 3.98 (2H, t, J = 6.4 Hz), 4.08 (3H, s), 6.91−7.01 (3H, m), 7.19−7.24 (1H, m), 7.57−7.61 (2H, m), 7.96 (1H, s).

  The compounds of Examples 92 to 94 below were produced in the same manner as in Example 91, using appropriate starting materials.

Example 92
1-ethyl-5-fluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 123-125 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.00 (3H, t, J = 7.3 Hz), 1.29 (3H, t, J = 6.8 Hz), 1.79-1.88 (2H, m), 3.76 (3H, s ), 4.03 (2H, t, J = 6.5 Hz), 4.52 (2H, q, J = 6.8 Hz), 6.91−7.02 (3H, m), 7.22−7.27 (1H, m), 7.60 (2H, d, J = 8.7 Hz), 8.00 (1H, s).

Example 93
1- (2-Ethoxyethyl) -5-fluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 108-109 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.96-1.09 (6H, m), 1.77-1.89 (2H, m), 3.65 (2H, t, J = 5.0 Hz), 3.78 (3H, s), 4.02 (2H, t, J = 6.8 Hz), 4.72 (2H, t, J = 5.0 Hz), 6.94−7.04 (3H, m), 7.23−7.29 (1H, m), 7.57 (2H, d, J = 8.7 Hz), 7.93 (1H, s).

Example 94
1-cyclopropylmethyl-5-fluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one pale yellow powder (n-hexane)
Melting point 60-62 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 0.36−0.51 (4H, m), 1.07 (3H, t, J = 7.4 Hz), 1.26−1.30 (1H, m), 1.86−1.94 (2H, m) , 4.09 (2H, t, J = 6.5 Hz), 6.96−7.08 (3H, m), 7.28−7.33 (1H, m), 7.61−7.66 (2H, m), 8.05 (1H, s).

Example 95
5-Fluoro-3- (4-hydroxyphenyl) -8-propoxy-1H-quinolin-4-one
A solution of 249 mg (0.76 mmol) of 5-fluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one in dichloromethane (5 ml) was cooled to −10 ° C. in a methanol-ice bath. To this was added 4.08 ml of 1N boron tribromide, and the mixture was stirred at room temperature for 6 hours. Ice water and dichloromethane were added to the reaction solution, and the resulting insoluble material was collected by filtration. The filtrate was separated and the organic layer was concentrated under reduced pressure. The residue and the filtrate were combined, and the mixture was purified by silica gel column chromatography (dichloromethane: methanol = 60: 1 → 25: 1). The purified product is concentrated under reduced pressure, crystallized by adding ethyl acetate to the residue, collected by filtration, washed with ethyl acetate, and dried to give a pale yellow powder of 5-fluoro-3- (4-hydroxyphenyl)- 220 mg (yield 92%) of 8-propoxy-1H-quinolin-4-one was obtained.
Melting point 271-272 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.03 (3H, t, J = 7.3Hz), 1.78−1.87 (2H, m), 4.08 (2H, t, J = 6.4Hz), 6.77 (2H, d , J = 8.6Hz), 6.87 (1H, dd, J = 8.8 Hz, J = 12.1Hz), 7.12 (1H, dd, J = 3.9 Hz, J = 8.8Hz), 7.41 (2H, d, J = 8.6 Hz), 7.77 (1H, s), 9.43 (1H, brs), 11.20 (1H, brs).

Example 96
5-Fluoro-8-hydroxy-3- (4-hydroxyphenyl) -1H-quinolin-4-one 5-fluoro-8-methoxy-3- (4-methoxyphenyl) -1H-quinolin-4-one 0 g (3.34 mmol) was suspended in 40 ml dichloromethane and the suspension was cooled to −10 ° C. in a methanol-ice bath. To this was added 17 ml of 1N boron tribromide and the resulting mixture was stirred at room temperature for 15 hours. Ice water and dichloromethane were added to the reaction solution, and the resulting insoluble material was collected by filtration. The residue was washed with water, dried, and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1 → 8: 1 → ethyl acetate: methanol = 4: 1). The purified product was concentrated under reduced pressure, crystallized by adding ethyl acetate to the residue, collected by filtration, washed with ethyl acetate, dried and dried as a light gray powder of 5-fluoro-8-hydroxy-3- (4 -Hydroxyphenyl) -1H-quinolin-4-one 360 mg (yield 40%) was obtained.
Melting point 303-305 ° C (decomposition)
¹ H-NMR (DMSO-d ₆ ) δppm: 6.74-6.82 (3H, m), 6.94 (1H, dd, J = 4.1 Hz, J = 8.5 Hz), 7.41 (2H, d, J = 8.3 Hz), 7.74 (1H, s), 9.46 (1H, brs), 10.70 (1H, brs), 11.32 (1H, brs).

Example 97
5-Fluoro-3- (4-hydroxy-2-methoxyphenyl) -8-propoxy-1H-quinolin-4-one
5-fluoro-3- (4-isopropoxy-2-methoxyphenyl) -8-propoxy-1H-quinolin-4-one 120 mg (0.31 mmol) in dichloromethane (5 ml) was added to 108 mg (0.81 Mmol) and the mixture was stirred at room temperature for 1 hour. Water and dichloromethane were added to the reaction solution, liquid separation was performed, and the organic layer was washed with water. The washed organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 10: 1). The purified product was concentrated under reduced pressure, and the residue was recrystallized from ethyl acetate to give white powder of 5-fluoro-3- (4-hydroxy-2-methoxyphenyl) -8-propoxy-1H-quinolin-4-one 100 mg. (Yield 90%) was obtained.
Melting point 251-253 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.01-1.07 (3H, t, J = 7.4 Hz), 1.77-1.88 (2H, m), 3.63 (3H, s), 4.07-4.12 (2H, t, J = 6.6 Hz), 6.33-6.43 (2H, m), 6.84-6.90 (1H, m), 7.02-7.11 (2H, m), 7.61-7.64 (1H, m), 9.39 (1H, s), 11.07 (1H, brs).

  The compound of Example 98 below was produced in the same manner as in Example 97, using appropriate starting materials.

Example 98
5-Fluoro-3- (2-hydroxy-4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one white powder (ethyl acetate)
Melting point 208-209 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.02 (3H, t, J = 7.5 Hz), 1.81-1.90 (2H, m), 3.73 (3H, s), 4.11 (2H, t, J = 6.5 Hz ), 6.43−6.51 (2H, m), 6.98−7.06 (1H, m), 7.16−7.25 (2H, m), 7.95 (1H, s), 10.23 (1H, s), 11.93 (1H, brs).

Example 99
5-Fluoro-8-hydroxy-3- (4-methoxyphenyl) -1H-quinolin-4-one 5-fluoro-8-methoxymethoxy-3- (4-methoxyphenyl) -1H-quinolin-4-one 350 mg To an ethanol solution (18 ml) of (1.06 mmol) was added 6.0 ml of 2N hydrochloric acid, and the mixture was stirred at 55 ° C. for 1 hour. The mixture after stirring was cooled to room temperature, and 11.6 ml of 1N sodium hydroxide was added to adjust the pH to 3-4. The pH-adjusted mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane: methanol = 50: 1 → 20: 1). The purified product is concentrated under reduced pressure, and the residue is crystallized from ethanol, collected by filtration, washed with ethanol, and dried to give a pale brown powder of 5-fluoro-8-hydroxy-3- (4-methoxyphenyl)- 165 mg (54% yield) of 1H-quinolin-4-one was obtained.
Melting point 270-272 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 3.75 (3H, s), 6.79 (1H, dd, J = 8.5 Hz, J = 12.1 Hz), 6.90−6.97 (3H, m), 7.53 (2H, d , J = 8.6Hz), 7.77 (1H, s), 10.60 (1H, brs), 11.40 (1H, brs).

Example 100
5-Fluoro-3- (2-hydroxymethylthiophen-3-yl) -8-propoxy-1H-quinolin-4-one
120 mg (0.39 mmol) of 3- (5-fluoro-4-oxo-8-propoxy-1,4-dihydroquinolin-3-yl) thiophene-2-carbaldehyde was suspended in 5 ml of ethanol and the suspension was suspended. 19.24 mg of sodium borohydride was added and the resulting mixture was stirred at room temperature for 1 hour. Dichloromethane was added to the reaction solution and washed with water. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1). The purified product is concentrated under reduced pressure, and the residue is recrystallized from ethyl acetate to give 5-fluoro-3- (2-hydroxymethylthiophen-3-yl) -8-propoxy-1H-quinolin-4-one as a white powder. 110 mg (yield 82%) was obtained.
Melting point 181-184 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.01 (3H, t, J = 7.3 Hz), 1.79-1.88 (2H, m), 4.07 (2H, t, J = 6.4 Hz), 4.47 (2H, d , J = 5.4 Hz), 5.48 (1H, t, J = 5.4 Hz), 6.87−6.96 (1H, m), 7.11−7.19 (2H, m), 7.39−7.40 (1H, m), 7.88 (1H, s), 11.36 (1H, brs).

Example 101
5-Fluoro-8- (3-hydroxypropoxy) -3- (4-methoxyphenyl) -1H-quinolin-4-one 8- (3-benzyloxypropoxy) -5-fluoro-3- (4-methoxyphenyl) ) -1H-quinolin-4-one 1.95 g (4.49 mmol) and 720 mg of 10% palladium on carbon were added to 50 ml of ethanol, and the mixture was stirred under hydrogen atmosphere (1 atm) at 50 ° C. for 7.5 hours for contact. Reduced. The reaction mixture was cooled to room temperature, filtered through Celite to remove the catalyst, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 80: 1 → 20: 1). The purified product was concentrated under reduced pressure, and the residue was concentrated to dryness to give a pale brown amorphous solid 5-fluoro-8- (3-hydroxypropoxy) -3- (4-methoxyphenyl) -1H-quinoline-4- 820 mg (53% yield) of ON was obtained.
¹ H-NMR (DMSO-d ₆ ) δppm: 1.92−2.02 (2H, m), 3.65 (2H, t, J = 5.9Hz), 4.20 (2H, t, J = 6.2Hz), 4.59 (1H, brs ), 6.84−6.95 (3H, m), 7.14 (1H, dd, J = 3.9 Hz, J = 8.8Hz), 7.55 (2H, d, J = 8.7Hz), 7.80 (1H, s), 11.27 (1H , brs).

  The compound of Example 102 below was prepared in the same manner as in Example 101 above, using appropriate starting materials.

Example 102
5-Fluoro-8- (2-hydroxypropoxy) -3- (4-methoxyphenyl) -1H-quinolin-4-one white powder (ethyl acetate)
Melting point: 216-218 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.19 (3H, d, J = 6.2Hz), 3.76 (3H, s), 3.82−4.12 (3H, m), 5.25 (1H, brs), 6.84−6.96 (3H, m), 7.12 (1H, dd, J = 3.9 Hz, J = 8.8Hz), 7.56 (2H, d, J = 8.8Hz), 7.86 (1H, s), 11.20 (1H, brs).

  The compounds of Examples 103 to 104 below were produced in the same manner as in Example 1 using appropriate starting materials.

Example 103
5-Chloro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one light brown powder (ethyl acetate)
Melting point 194-196 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.03 (3H, t, J = 7.3Hz), 1.80-1.87 (2H, m), 3.76 (3H, s), 4.11 (2H, t, J = 6.4Hz ), 6.93 (2H, d, J = 8.6Hz), 7.12 (1H, d, J = 8.5Hz), 7.17 (1H, d, J = 8.5Hz), 7.54 (2H, d, J = 8.6Hz), 7.80 (1H, s), 11.23 (1H, brs).

Example 104
5-Bromo-8-cyclopentyloxy-3- (4-methoxyphenyl) -1H-quinolin-4-one light brown powder (ethanol)
Melting point 213-215 ° C
¹ H-NMR (DMSO-d ₆ ) δppm: 1.59-1.70 (2H, m), 1.71-2.00 (6H, m), 3.75 (3H, s), 4.97-5.00 (1H, m), 6.94 (2H, d, J = 8.7Hz), 7.04 (1H, d, J = 8.5Hz), 7.40 (1H, d, J = 8.4Hz), 7.53 (2H, d, J = 8.7Hz), 7.81 (1H, s) , 11.20 (1H, brs).

Pharmacological test 1
Measurement of mitochondrial function improvement using 1-methyl-4-phenylpyridinium (MPP ⁺ ) -treated human neuroblastoma line SH-SY5Y
Human neuroblastoma line SH-SY5Y with impaired mitochondrial function by MPP ⁺ treatment [Bollimuntha S. et al., J Biol Chem, 280, 2132-2140 (2005) and Shang T. et al., J Biol Chem, 280, 34644 -34653 (2005)], the measured mitochondrial redox activity using Alamar Blue fluorescent dye after compound addition was used as an index [Nakai M. et al., Exp Neurol, 179, 103-110 (2003)]. The improvement effect was evaluated.

The human neuroblastoma strain SH-SY5Y uses Dulbecco's modified Eagle's medium containing 10% fetal calf serum (DMEM, containing 50 units / ml penicillin and 50 μg / ml streptomycin as antibiotics), 37oC, 5% carbonic acid. Culture was performed under gas conditions. The cells were seeded in a 96-well (well) black plate coated with poly-D-lysine at a concentration of 3-6 × 10 ⁴ cells / cm ² (medium amount 100 μl / well) and cultured in the above medium for 2 days. Furthermore, the medium was exchanged (100 μl / well) to the same medium in which DMEM (N2-DMEM) or 1.5 mM MPP ⁺ containing 1% N2 supplement was dissolved, and cultured for 39 to 48 hours, and then used for a mitochondrial redox activity measurement system. A test compound previously dissolved in dimethyl sulfoxide (DMSO) was diluted with N2-DMEM and added in a volume of 10 μl / well 24 hours before the activity measurement (final compound concentration 0.01-1 μg / ml).

  After removing the medium by suction, balanced salt solution containing 10% Alamar Blue (154 mM sodium chloride, 5.6 mM potassium chloride, 2.3 mM calcium chloride, 1.0 mM magnesium chloride, 3.6 mM sodium bicarbonate, 5 mM glucose, 5 mM hepes, pH 7.2) is added at a volume of 100 μL / well, reacted in a 37oC thermostat for 1 hour, and then the fluorescence intensity is detected with a fluorescence detector (Hamamatsu Photonics, excitation wavelength 530 nm, measurement wavelength 580 nm). Thus, mitochondrial redox activity was measured.

The relative fluorescence intensity of cells cultured in a medium containing MPP ⁺ and each test compound is shown relative to the fluorescence intensity in the wells of cells cultured in a medium containing only DMSO (final concentration 0.1%). It was. In the MPP ⁺ treated cell group, the test compound showing higher fluorescence intensity than the addition of DMSO alone was considered to have an effect of improving mitochondrial function.

Pharmacological test 2
Measurement of dopamine neuroprotective activity using C57BL / 6 mice treated with 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP)
It is a marker protein of dopaminergic neurons in the striatum region of the brain after administration of the compound using mice [Chan P. et al., J Neurochem, 57, 348-351 (1991)] in which dopaminergic nerves were injured by MPTP treatment The dopamine content at the same site as the protein level of tyrosine hydroxylase (TH) and dopamine transporter (DAT) is the index [Mori A. et al., Neurosci Res, 51, 265-274 (2005)]. evaluated.

  Male C57BL / 6 mice (10-12 weeks old, Nippon Charles River Co., Ltd.) were used as test animals. MPTP was dissolved in physiological saline to a concentration of 4 mg / ml and subcutaneously administered to mice at a volume of 10 ml / kg. The test compound was suspended in 5% gum arabic / saline (w / v) to a concentration of 1 mg / ml. 30 minutes, 24 hours, and 48 hours after administration of MPTP to mice, each test compound or its solvent was orally administered in a volume of 10 ml / kg. The mice were decapitated 72 hours after MPTP administration, the brain was removed, and the left and right striatum were removed.

The left striatum was used as a protein level analysis sample by Western blotting. Each tissue was treated with hepes buffered sucrose solution (0.32 M sucrose, 4 μg / ml pepstatin, 5 μg / ml aprotinin, 20 μg / ml trypsin inhibitor, 4 μg / ml leupeptin, 0.2 mM phenylmethanesulfonyl fluoride, 2 mM ethylenediamine. Homogenize in tetraacetic acid (EDTA), 2 mM ethylene glycol bis (β aminoethyl ether) tetraacetic acid, 20 mM hepes, pH 7.2), and perform protein quantification using the bicinchoninic acid kit for protein quantification (Pierce) It was. Each homogenate sample of the same protein amount dissolved in the Remley sample buffer was electrophoresed through a sodium dodecyl sulfate-polyacrylamide gel. Proteins separated by electrophoresis were electrically transferred to a polyvinylidene fluoride membrane. The membrane was divided into TH, DAT, and housekeeping proteins (ie, sodium-potassium TPase (Na ⁺ / K ⁺ -ATPase) α1 subunit and actin (Na ⁺ / K ⁺ -ATPase manufactured by Upstate Biotechnology), Others were reacted with specific primary antibodies against Chemicon))). Thereafter, a horseradish peroxidase-labeled secondary antibody (Amersham) was bound to each primary antibody, and chemiluminescence derived from the enzyme activity of peroxidase was detected with an X-ray film. The protein band density on the film was analyzed with a densitometer (Biorad), and the TH value for Na ⁺ / K ⁺ -ATPase and the DAT value for actin were calculated.

  The right striatum was used as a dopamine content analysis sample by measuring the tissue weight immediately after extraction. Each tissue was homogenized in a 0.1 N perchloric acid solution containing isoproterenol as an internal standard substance for measurement while cooling with ice using an ultrasonic crusher. The supernatant obtained after centrifuging the homogenate at 20000 g and 4 ° C for 15 minutes was subjected to high performance liquid chromatography (manufactured by Aicom) using a reverse phase column. The mobile phase, 15% methanol-0.1 M citrate / 0.1 M sodium acetate buffer (190 mg / l sodium 1-octanesulfonate and 5 mg / l EDTA, pH 3.5) was flowed at a flow rate of 0.5 ml / min. The dopamine peak of each sample was detected using an electrochemical detector (applied voltage +750 mV vs Ag / AgCl, manufactured by Eicom). The dopamine content per tissue weight in each sample was calculated from the identified dopamine peak using analysis software (Gilson).

  In both analyses, the value of the sample derived from the MPTP-treated mouse treated with only the test compound or the solvent was relatively shown with the value of the sample derived from the MPTP-untreated mouse as 100%. Statistical processing was performed using a non-clinical statistical analysis system, and a significant difference was found when the significance value was lower than 0.05. In MPTP-treated mice, increase in protein level was observed in each test drug administration group relative to the solvent administration group, and when there was a significant difference in t-test between the two groups, dopamine neuroprotective effect was considered .

Claims (7)

General formula (1)

[Where:
R ₁ represents hydrogen, a lower alkyl group, a cycloC3-C8 alkyl lower alkyl group or a lower alkoxy lower alkyl group.
R ₂ represents hydrogen, a lower alkyl group or a halogen-substituted lower alkyl group.
R ₃ represents a phenyl group, a furyl group, a thienyl group or a pyridyl group.
Here, one or more groups selected from the group consisting of the following (1) to (16) may be substituted on the aromatic ring and heterocyclic ring represented by R ₃ :
(1) a lower alkyl group,
(2) a lower alkoxy group,
(3) a halogen-substituted lower alkoxy group,
(4) phenoxy group,
(5) a lower alkylthio group,
(6) a hydroxy group,
(7) hydroxy lower alkyl group,
(8) halogen,
(9) a lower alkanoyl group,
(10) a lower alkoxycarbonyl group,
(11) an amino group optionally substituted by one or more lower alkyl groups,
(12) a carbamoyl group optionally substituted by one or more lower alkyl groups,
(13) a cyclo C3-C8 alkyl lower alkoxy group,
(14) pyrrolidinylcarbonyl group,
(15) A morpholinylcarbonyl group and (16) a carboxyl group R ₄ represent halogen.
R ₅ represents hydrogen or halogen.
R ₆ represents hydrogen.
R ₇ represents any one of the following groups (1) to (15).
(1) a hydroxy group,
(2) halogen,
(3) a lower alkoxy group,
(4) a halogen-substituted lower alkoxy group,
(5) hydroxy lower alkoxy group,
(6) Lower alkoxy lower alkoxy group,
(7) an amino group which may be substituted with one or more groups selected from the group consisting of a lower alkyl group, a lower alkoxy lower alkyl group and a cyclo C3-C8 alkyl group;
(8) Amino lower alkoxy group (here, selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkylsulfonyl group, and a carbamoyl group optionally having one or more lower alkyl groups on the amino group) One or more groups may be present),
(9) a cyclo C3-C8 alkyloxy group,
(10) a cyclo C3-C8 alkyl lower alkoxy group,
(11) Tetrahydrofuryl lower alkoxy group,
(12) a lower alkylthio group,
(13) A heterocyclic group selected from the group consisting of a morpholinyl group, a pyrrolidinyl group, a furyl group, a thienyl group, and a benzothienyl group,
(14) phenyl lower alkoxy lower alkoxy group, and (15) pyrrolidinylcarbonyl group]
The pharmaceutical which consists of quinolone compound represented by these, or its salt. R ₁ represents hydrogen or a lower alkyl group, R ₂ represents hydrogen or a lower alkyl group, on the aromatic ring and heterocyclic ring represented by R ₃ is a phenyl group or a pyridyl group (said R _3, below (1) , (2), (6) and (8) may be substituted by one or two groups selected from the group consisting of:
(1) a lower alkyl group,
(2) a lower alkoxy group,
(6) a hydroxy group,
(8) halogen), R ₄ represents halogen, R ₅ represents hydrogen, R ₆ represents hydrogen, and R ₇ represents the following (3), (4) and (7):
(3) a lower alkoxy group,
(4) a halogen-substituted lower alkoxy group,
(7) From the quinolone compound represented by the general formula (1) according to claim 1 or a salt thereof, which represents any one of amino groups optionally substituted by one or two lower alkyl groups The medicine which becomes. A pharmaceutical comprising the quinolone compound represented by the general formula (1) according to claim 2 or a salt thereof selected from the group shown below:
5-fluoro-3- (4-methoxyphenyl) -2-methyl-8-propoxy-1H-quinolin-4-one,
5-fluoro-3- (4-methoxyphenyl) -1-methyl-8-propoxy-1H-quinolin-4-one,
3- (2,4-dimethoxyphenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one,
5-fluoro-8-isopropoxy-3- (4-methoxyphenyl) -1H-quinolin-4-one,
3- (2,4-dichlorophenyl) -5-fluoro-8-propoxy-1H-quinolin-4-one,
8-ethoxy-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one,
5-fluoro-3- (4-methoxy-2-methylphenyl) -8-propoxy-1H-quinolin-4-one,
5-fluoro-3- (4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one,
5-fluoro-3- (2-fluoro-4-methoxyphenyl) -8-propoxy-1H-quinolin-4-one,
5-fluoro-3- (4-hydroxyphenyl) -8-propoxy-1H-quinolin-4-one,
8-cyclopropylmethoxy-5-fluoro-3- (4-methoxyphenyl) -1H-quinolin-4-one,
5-fluoro-8-propoxy-3-pyridin-4-yl-1H-quinolin-4-one,
5-fluoro-3- (4-methoxyphenyl) -8- (N-methyl-N-propylamino) -1H-quinolin-4-one, and 5-fluoro-3- (4-methoxyphenyl) -8- (4,4,4-trifluorobutoxy) -1H-quinolin-4-one. A pharmaceutical composition comprising the pharmaceutical according to any one of claims 1 to 3 and a pharmacologically acceptable carrier. A therapeutic and prophylactic agent for neurodegenerative diseases comprising the pharmaceutical according to any one of claims 1 to 3 as an active ingredient ,
The neurodegenerative disease is Parkinson's disease, Parkinson's syndrome, juvenile parkinsonism, striatal nigra degeneration, progressive supranuclear paralysis, Alzheimer's disease, Pick's disease, prion disease, basal ganglia degeneration, diffuse Lewy body disease, Huntington's disease, essential tremor, Gilles de la Tourette syndrome, Rett syndrome, athetosis, cerebral palsy, Wilson disease, Hallelfolden spats syndrome, neuroaxonal dystrophy, spinocerebellar degeneration, Olive Bridge cerebellar atrophy, Joseph's disease, dentate nucleus red nucleus pallidal Louis atrophy, Gerstmann-Stroisler-Scheinka syndrome, Friedreich's ataxia, May-White syndrome, telangiectasia ataxia, muscle atrophy Lateral sclerosis, bulbar spinal muscular atrophy, Weldnig-Hoffmann disease, Kugelberg-Wehlander disease Hereditary spastic paraplegia, syringomyelia, medullary cavernosis, Arnold Kiary malformation, spina bifida, Sjogren-Larson syndrome, age-related macular degeneration, and / or dysfunction associated with cerebral infarction and / or cerebral hemorrhage The therapeutic and prophylactic agent for the neurodegenerative disease, which is a disease selected from the group consisting of neuroleptic symptoms . A therapeutic and prophylactic agent for a disease associated with a disorder of nerve function, comprising the pharmaceutical according to any one of claims 1 to 3 as an active ingredient ,
Diseases associated with the impaired neurological function are spinal cord injury, chemotherapy-induced neuropathy, diabetic neuropathy, radioactive disorder, and multiple sclerosis, acute disseminated encephalomyelitis, transverse myelitis, progressive Therapeutic and preventive agent for diseases associated with impaired neurological function, which is a demyelinating disease selected from multifocal leukoencephalopathy, subacute sclerosing panencephalitis, chronic inflammatory demyelinating polyradiculoneuritis and Guillain-Barre syndrome . A therapeutic and prophylactic agent for diseases associated with a decrease in mitochondrial function, comprising the pharmaceutical according to any one of claims 1 to 3 as an active ingredient ,
The diseases associated with the decrease in mitochondrial function are Pearson's syndrome, diabetes, hearing loss, malignant migraine, Leber's disease, MELAS, MARF, MERRF, MARF / Melas duplication syndrome, NARP, pure myopathy, mitochondrial cardiomyopathy, Myopathy, dementia, gastrointestinal ataxia, acquired ironblastic anemia, aminoglycoside-induced hearing loss, complex III deficiency due to cytochrome b gene mutation, symmetric multiple lipomatosis, ataxia, myoclonus, retinopathy, MNGIE, ANT1 abnormality, Twinkle abnormality, POLG abnormality, repetitive myoglobinuria, SANDO, ARCO, complex I deficiency, complex II deficiency, optic nerve atrophy, complex IV deficiency severe infant type, mitochondrial DNA deficiency syndrome, Leigh encephalopathy, chronic progressive extraocular palsy syndrome (CPEO), Keynes-Sayer syndrome, encephalopathy, lactic acidemia, myoglobinuria, drug-induced mito Undria disease, schizophrenia, major depressive disorder, bipolar type I disorder, bipolar type II disorder, atypical depression, seasonal emotional disorder, postpartum depression, mild depression, recurrent short-term depressive disorder, intractable A therapeutic and prophylactic agent for diseases associated with a decrease in mitochondrial function, such as sexual depression, chronic depression, double depression and acute renal failure .